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exploring factors associated with health-related quality of
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Background: At present, red blood cells (RBCs) are stored for up to 42 days prior to transfusion.
The relative effectiveness and safety of different RBC storage times prior to transfusion is uncertain.
Objective: To assess the clinical effectiveness and cost-effectiveness of transfusing fresher RBCs (stored for
≤ 7 days) compared with current standard-aged RBCs in critically ill patients requiring blood transfusions.
Design: The international Age of BLood Evaluation (ABLE) trial was a multicentre, randomised, blinded trial
undertaken in Canada, the UK, the Netherlands and France. The UK trial was funded to contribute
patients to the international trial and undertake a UK-specific health economic evaluation.
Setting: Twenty intensive care units (ICUs) in the UK, as part of 64 international centres.
Participants: Critically ill patients aged ≥ 18 years (≥ 16 years in Scotland) expected to require mechanical
ventilation for ≥ 48 hours and requiring a first RBC transfusion during the first 7 days in the ICU.
Interventions: All decisions to transfuse RBCs were made by clinicians. One patient group received
exclusively fresh RBCs stored for ≤ 7 days whenever transfusion was required from randomisation until
hospital discharge. The other group received standard-issue RBCs throughout their hospital stay.
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Main outcome measures: The primary outcome was 90-day mortality. Secondary outcomes included
development of organ dysfunction, new thrombosis, infections and transfusion reactions. The primary
economic evaluation was a cost–utility analysis.
Results: The international trial took place between March 2009 and October 2014 (UK recruitment took
place between January 2012 and October 2014). In total, 1211 patients were assigned to receive fresh
blood and 1219 patients to receive standard-aged blood. RBCs were stored for a mean of 6.1 days [standard
deviation (SD) ± 4.9 days] in the group allocated to receive fresh blood and 22.0 days (SD ± 8.4 days) in the
group allocated to receive standard-aged blood. Patients received a mean of 4.3 RBC units (SD ± 5.2 RBC
units) and 4.3 RBC units (SD ± 5.5 RBC units) in the groups receiving fresh blood and standard-aged blood,
respectively. At 90 days, 37.0% of patients in the group allocated to receive fresh blood and 35.3% of
patients in the group allocated to receive standard-aged blood had died {absolute risk difference 1.7%
[95% confidence interval (CI) –2.1% to 5.5%]}. There were no between-group differences in any secondary
outcomes. The UK cohort comprised 359 patients randomised and followed up for 12 months for the
cost–utility analysis. UK patients had similar characteristics and outcomes to the international cohort. Mean
total costs per patient were £32,346 (95% CI £29,306 to £35,385) in the group allocated to receive fresh
blood and £33,353 (95% CI £29,729 to £36,978) in the group allocated to receive standard-aged blood.
Approximately 85% of the total costs were incurred during the index hospital admission. There were no
significant cost differences between the two groups [mean incremental costs for those receiving fresh vs.
standard-aged blood: –£231 (95% CI –£4876 to £4415)], nor were there significant differences in outcomes
(mean difference in quality-adjusted life-years –0.010, 95% CI –0.078 to 0.057).
Limitations: Adverse effects from the exclusive use of older RBCs compared with standard or fresh RBCs
cannot be excluded.
Conclusions: The use of RBCs aged ≤ 7 days confers no clinical or economic benefit in critically ill patients
compared with standard-aged RBCs.
Future work: Future studies should address the safety of RBCs near the end of the current permitted
storage age.
Trial registration: Current Controlled Trials ISRCTN44878718.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 62.
See the NIHR Journals Library website for further project information. The international ABLE trial was also
supported by peer-reviewed grants from the Canadian Institutes of Health Research (177453), Fonds de
Recherche du Québec - Santé (24460), the French Ministry of Health Programme Hospitalier de Recherche
Clinique (12.07, 2011) and by funding from Établissement Français du Sang and Sanquin Blood Supply.
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Plain English summary
Many critically ill patients require blood transfusions to treat anaemia in order to maintain the body’sability to transport oxygen to cells. Donated blood is currently stored for up to 42 days in blood
banks before being transfused. Before the trial, it was known that the blood changes during this storage
time. There was widespread concern that older blood might be less safe and effective, but there were no
large clinical trials that explored whether or not using the freshest blood (stored for 1 week or less) was
better than the current standard storage time of about 3 weeks.
The Age of BLood Evaluation (ABLE) trial was an international trial undertaken in 64 intensive care units in
Canada (the lead country), the UK (where the Health Technology Assessment programme funded the trial),
the Netherlands and France. Just over 2500 patients who required a blood transfusion in the intensive
care unit were allocated by chance to either receive blood transfusions using only the freshest blood
(aged 1 week or less) whenever they needed a blood transfusion, or blood stored for the current standard
time of about 3 weeks. In the UK, 359 patients participated; these patients were followed up for 12 months.
We found that a similar number of patients in each group died during the 3 months after participating in
the trial (37.0% of patients in the group allocated to receive fresh blood and 35.3% of patients in
the group allocated to receive standard-aged blood). We found no differences in any other important
complications (organ failures, infections, length of time in hospital or transfusion complications). In the UK
participants, we also found that there were no differences in patients’ quality of life or illness costs
between the groups (based on the 6- and 12-month follow-up points).
The study showed that there are no benefits from using the freshest blood for transfusions in critically ill
patients compared with using standard-aged blood transfusions, as is current practice.
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Scientific summary
Background
Donated red blood cells (RBCs) can be stored for up to 35 days in the UK (and up to 42 days in some countries).
Historically, the shelf life of RBCs was established based upon biochemical standards and RBC survival studies
were conducted in healthy volunteers. Despite the daily use of RBCs in hospitals worldwide, there was no
high-quality clinical research to determine whether or not older stored RBCs deliver oxygen to tissues as
effectively as fresher RBCs. Current standards for approval of RBC products are based on characteristics of the
product, especially RBC survival in vivo at 24 hours, but not on the ability of cells to transport oxygen to tissues.
Prior to the Age of BLood Evaluation (ABLE) trial, an accumulating body of laboratory and clinical research had
raised the possibility that stored RBCs may be ineffective or may even have harmful effects on patients. None of
this evidence was conclusive, but the signals seen in some uncontrolled observational clinical studies, together
with the widespread use of RBC transfusions, meant that this research question was of vital importance to
ensure RBCs are used safely and effectively in the future. The ABLE study was an international trial, led from
Canada, which recruited patients in Canada, the UK, the Netherlands and France. The Health Technology
Assessment (HTA) programme funded a UK-based arm of the study with the intention of contributing to
international recruitment and undertaking a UK-specific health economic evaluation.
Objectives
The primary objective of the international ABLE trial was to determine whether or not, in critically ill
adult patients requiring RBC transfusion, transfusing fresher RBCs stored for ≤ 7 days compared with
standard-issue RBCs stored for up to 35 days decreases mortality, organ failures and new infections.
Additional objectives for the UK arm of the trial were to:
l establish whether or not, in critically ill adult patients, the use of RBCs stored for ≤ 7 days compared
with standard-issue RBCs stored for up to 35 days improves health-related quality of life (HRQoL)
l establish the cost-effectiveness of transfusion using RBCs stored for ≤ 7 days compared with
standard-issue RBCs stored for up to 35 days
l undertake a substudy comparing two measures of HRQoL, the EuroQol-5 Dimensions (EQ-5D),
three-level version (EQ-5D-3L) and the five-level version (EQ-5D-5L), at 6 and 12 months post
randomisation among survivors
l undertake an exploratory study of factors associated with HRQoL and health-care costs during
12 months’ follow-up following critical illness.
Methods
Study design
The ABLE study was an international double-blind, multicentre, randomised clinical trial. Follow-up was to
6 months for survival only across the international cohort, but in the UK, follow-up was to 12 months post
randomisation for survival; HRQoL and health-care resource use data were collected.
Study end points
Primary end point
Ninety-day all-cause mortality.
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Secondary end points
1. Intensive care unit (ICU) and hospital mortality; 28-day, 6- and 12-month mortality; survival times.
2. Number of organ failures developing; multiple organ dysfunction score; time to development of organ
failure; highest number of organ failures per patient.
3. New infections (including nosocomial pneumonia, deep-tissue infections and bacteraemia).
4. Duration of respiratory, haemodynamic and renal support.
5. Length of hospital and ICU stay.
6. Adverse event rates, including transfusion reactions.
7. Health-related quality of life at 6 and 12 months, measured using the EQ-5D questionnaire.
Population
Inclusion criteria
All admissions to the ICU were potentially eligible for up to 7 days following admission and were tracked
using screening logs for the following criteria.
1. The patient had a request for a first RBC unit transfusion in the ICU.
2. The patient had an anticipated length of invasive and/or non-invasive mechanical ventilation (MV) of at
least 48 hours once enrolled, as estimated by the attending physician.
Exclusion criteria
Exclusion criteria were classified into clinical criteria and transfusion laboratory criteria.
Clinical criteria
1. Patients who were aged < 16 years.
2. Patients previously enrolled in the ABLE study.
3. Patients who had already been transfused with RBCs during the current hospitalisation.
4. Patients who had an obvious terminal illness documented in the medical record with a life expectancy
of < 3 months.
5. Patients who had undergone routine cardiac surgical care.
6. Patients in whom a decision to withdraw/withhold critical care had been made (including patients with
probable or proven brain death).
Transfusion laboratory criteria
1. No RBCs with a storage time of ≤ 7 days were available in the transfusion laboratory or could not be
supplied for other reasons at the time of eligibility and potential randomisation.
2. Patients requiring urgent transfusion of > 1 unit of uncross-matched RBCs.
3. Patients who had a known objection to blood transfusions.
4. Patients who planned to receive autologous-donated RBCs.
5. Patients who posed difficulties in securing blood products (having a rare blood type) and were difficult
to match.
Interventions
Patients were randomised to one of two groups, receiving either of:
1. Standard-issue RBCs (average storage age: 18–21 days). In this group, the blood bank provided RBCs
according to its usual practice, which was typically to use group-specific blood towards the end of the
stocked RBC age in order to minimise wastage.
2. Red blood cells stored for ≤ 7 days. In this group, the blood banks controlled the storage age of RBCs
to provide the freshest available RBCs in the storage range of 2–7 days whenever possible.
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The intervention lasted until hospital discharge or death, and RBCs were provided whenever blood
transfusion was prescribed by clinicians.
Screening and consent
Patients were screened in the ICU by clinicians and research staff. The recruitment window started from
the decision to transfuse RBCs, and its duration was largely determined by the urgency of transfusion.
Consent required a flexible approach because the majority of participants lacked mental capacity, and
included the consent of relatives, welfare guardians and professional consultees, in accordance with
English and Scottish legal frameworks.
Randomisation and blinding
Randomisation was undertaken by research staff within the participating ICUs via a remote randomised
system based in the Ottawa Health Research Centre. Group allocation was restricted to the hospital
transfusion laboratory in order to maintain blinding of clinical and research teams in the ICU throughout
the intervention. Allocation was stratified by trauma versus other critically ill patients, and by study centre.
Randomisation comprised a computer-generated random listing of the treatment allocations using a
pre-established minimisation algorithm. Only the study statistician and designate at the co-ordinating
centre had knowledge of the randomisation codes.
All RBC units issued to patients had the expiry date (and date bled) concealed by application of an
adhesive label by the transfusion laboratory technician/biomedical scientist prior to issue to patients.
Accompanying documentation also had any expiry dates obscured.
Data collection
Baseline data included age, sex, hospital and ICU admission dates, type of admission, most responsible ICU
admission diagnosis, Acute Physiology and Chronic Health Evaluation II (APACHE II) score at ICU admission,
transfusion history during the 4 weeks prior to admission and significant comorbidities. Co-interventions
administered at randomisation were recorded, including MV, dialysis/renal replacement therapy and
cardiovascular support.
Hospital-based outcomes were collected by research staff from clinical records during hospitalisation.
Outcomes at 6 and 12 months were collected via postal and telephone contacts using questionnaires for
HRQoL (EQ-5D) and health resource use questionnaires. UK ICUs were randomised to use either the
EQ-5D-3L or the EQ-5D-5L questionnaire for the evaluation of these different measurement tools in the
critically ill population.
Results
The international trial cohort was recruited between March 2009 and May 2014 (with extension to
October 2014 for UK patients included in the health economic evaluation). In the international trial, 2510
patients underwent randomisation; 80 (3.2%) had no primary outcome data, leaving 2430 patients (1211
in the group allocated to receive fresh blood and 1219 in the group allocated to receive standard-aged
blood) in the intention-to-treat analysis. In total, 359 patients were recruited in the UK; 357 patients were
included in the economic evaluation.
Baseline data were available for 2412 of the 2430 patients with primary outcome data. Of these
2430 patients, 94 (3.9%) did not receive any RBC transfusions. The mean age was 61.2 years [standard
deviation (SD) ± 16.7 years] and 42.5% of patients had coexisting illnesses. The illness severity, based on
the APACHE II score and requirement for organ support, was high [mean 21.8 (SD ± 7.6)] and the majority
of patients had significant levels of organ dysfunction based on the multiple organ dysfunction syndrome
[MODS; mean MODS score of 4.9 points (SD ± 3.1 points); 97.4% of patients were receiving MV, 28.1%
were receiving renal replacement therapy and 62.8% were receiving vasoactive support]. Almost all
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patients were non-elective ICU admissions. The majority had a medical diagnosis (71.0%), most likely to be
consistent with the non-eligibility of patients receiving blood transfusion prior to ICU admission, which
excludes many surgical and trauma patients.
The mean pre-transfusion haemoglobin concentration was 7.69 g/dl (SD ± 1.28 g/dl) and 7.64 g/dl
(SD ± 1.09 g/dl) for the groups receiving fresh and standard-aged blood, respectively. Patients received
4.3 RBC units (SD ± 5.2 RBC units) and 4.3 RBC units (SD ± 5.5 RBC units) in the groups receiving fresh
and standard-aged blood, respectively. There was excellent separation of storage age profile: 6.1 days
(SD ± 4.9 days) in the group allocated to receive fresh blood versus 22.0 days (SD ± 8.4 days) in the group
allocated to receive standard-aged blood. The UK cohort was similar to the international cohort.
Primary outcome
In the international trial, at 90 days after randomisation, 37.0% (448/1211) of patients in the group
allocated to receive fresh blood and 35.3% (430/1219) of patients in the group allocated to receive
standard-aged blood had died {unadjusted absolute risk difference of 1.7% [95% confidence interval (CI)
–2.1% to 5.5%; p = 0.38]; adjusted absolute risk difference 1.7% [–1.6% to 4.9%]}. Outcomes restricted
to the UK cohort were similar: 32.4% (58/179) in the group allocated to receive fresh blood and 34.9% in
the group allocated to receive standard-aged blood (61/175).
Secondary outcomes
The survival analysis of the time to death showed a hazard ratio in the group allocated to receive fresh
blood, as compared with the group allocated to receive standard-aged blood, of 1.1 (95% CI 0.9 to 1.2;
p = 0.38). No significant difference in mortality was observed between the groups on the basis of follow-up
duration, age, number of units transfused, APACHE II score or admission category.
No significant differences were observed with respect to major illnesses, duration of respiratory,
haemodynamic, or renal support, or length of stay in the ICU or hospital. There were also no differences
in reported transfusion reactions.
The per-protocol analysis of the primary outcome that included only patients who received a transfusion
showed no difference between the groups in the international trial. The sensitivity analysis of the primary
outcome, in which the outcomes of patients in the group allocated to receive fresh blood who received
only red blood cells that had been stored for ≤ 7 days were compared with the outcomes of patients in
the group allocated to receive standard-aged blood who received red blood cells that had been stored for
> 7 days, also showed no differences between the groups.
A separate analysis restricted to the patients recruited in the UK suggested that the outcomes were similar,
and the effect sizes were very similar to the international cohort.
Cost–utility analysis
Taking missing data into account, the mean total costs per patient were £32,346 (95% CI £29,306 to
£35,385; n = 181) in the group allocated to receive fresh blood, and £33,353 (95% CI £29,729 to
£36,978; n = 176) in the group allocated to receive standard-aged blood. In both groups, approximately
85% of the total costs were incurred during the index hospital admission and 15% were incurred during
follow-up. The mean utility values were similar for the two groups over time. The mean total quality-adjusted
life-years (QALYs) per patient were 0.207 (95% CI 0.158 to 0.256) in the group allocated to receive fresh
blood, and 0.213 (95% CI 0.170 to 0.257) in the group allocated to receive standard-aged blood.
There were no significant differences in costs between the two groups [mean incremental cost for the
group allocated to receive fresh blood vs. the group allocated to receive standard-aged blood was –£231
(95% CI –£4876 to £4415)] or in outcomes [mean QALYs gained was 0.010 (95% CI –0.078 to 0.057)].
The incremental net monetary benefit for fresh blood versus standard-aged blood was not significantly
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxiv
different from zero at a maximum willingness to pay for a QALY of £20,000 (mean £25; 95% CI –£4587
to £4637) and £30,000 (mean –£77; 95% CI –£4821 to £4666).
Comparison of EuroQol-5 Dimensions, three-level version and EuroQol-5 Dimensions,
five-level version scores
After adjusting for patient characteristics, there were no significant differences in the conditional mean and
median EQ-5D-3L and EQ-5D-5L utility scores at 6 months (p ≥ 0.17), but there were significant differences
at 12 months (p < 0.05): the mean EQ-5D-5L scores were 0.15 units higher than the EQ-5D-3L scores,
and the median EQ-5D-5L scores were 0.20 units higher. However, the sample size was small and there
were limited data to enable adjustment for potentially important confounding factors such as patient
comorbidities.
Factors associated with health-care costs and health-related quality of life
None of the available covariates was a statistically significant predictor of utility scores at 6 or 12 months,
or of QALYs up to 12 months, for either all patients or survivors only. However, the number of available
covariates was limited, especially in relation to pre-existing and concurrent comorbidity and health status.
The majority (85%) of costs were incurred during the index hospitalisation. These were predicted by the
severity of organ dysfunction and whether or not the patient died in the ICU. Controlling for whether or
not the patient died, total costs increased with worsening MODS score by, on average, around £8000,
£19,000 and £21,000 per patient for those with scores of 5–8, 9–12 and ≥ 13 points, respectively,
compared with those with a score of 0–4 points. On average, the costs incurred by those who died were
£30,000 lower costs than the costs incurred by those who survived, and those with prior chronic
institutionalisation incurred total costs that were, on average, around £24,000 higher than those without
chronic institutionalisation. None of the other covariates was individually statistically significant as a
predictor of any of the cost measures, nor were they jointly significant when added to the models.
Conclusions
The ABLE trial found no clinically or statistically important benefit from transfusing exclusively RBCs stored
for ≤ 7 days compared with the current standard practices used in blood banks for treating critically ill
patients when a blood transfusion is required. There were no important differences between the UK
cohort and the international cohort in patient characteristics or outcomes.
The cost–utility analysis (restricted to the UK and undertaken from a NHS perspective) showed that there were
no differences in terms of costs and outcomes. The findings mean that there is no reason to prefer fresh blood
to standard-aged blood on the basis of differences in quality or length of life, or on cost grounds.
Trial registration
This trial is registered as ISRCTN44878718.
Funding
Funding for this study was provided by the HTA programme of the National Institute for Health Research.
The international ABLE trial was also supported by peer-reviewed grants from the Canadian Institutes of
Health Research (177453), Fonds de Recherche du Québec - Santé (24460), the French Ministry of Health
Programme Hospitalier de Recherche Clinique (12.07, 2011) and by funding from Établissement Français
du Sang and Sanquin Blood Supply.
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Chapter 1 Summary of trial rationale, existing
evidence, history of application (international
collaboration)
Background
Red blood cell (RBC) transfusion is a widely practised intervention for critically ill patients. Approximately
85 million RBC units are transfused annually worldwide, and just under 2 million in the UK. In severe cases
of anaemia or bleeding, reversal of dangerously low concentrations of haemoglobin can only be achieved
by RBC transfusion. However, the practice has recognised risks, including transfusion-associated lung
injury, transfusion-associated circulatory overload, bacterial contamination, infection transmission and
allergic reactions, although all of these are rare.1 Transfusion errors resulting in transfusion reactions are
also an important cause of morbidity and mortality.
Meta-analysis of randomised controlled trials (RCTs) has demonstrated that ‘restrictive’ transfusion practice
(using a lower haemoglobin concentration as a transfusion trigger, typically 70–80 g/l) appears to be safe
and leads to a reduction in overall RBC usage.2–4 The adoption of these restrictive haemoglobin transfusion
triggers has resulted in a substantial reduction in RBC use, especially for surgery, and forms a key component
of multimodal patient blood-management systems.
Donated RBCs can be stored for up to 35 days in the UK (and up to 42 days in some countries). Historically,
the shelf life of RBCs was based on biochemical standards and RBC survival studies conducted in healthy
volunteers. Despite the daily use of RBCs in hospitals worldwide, prior to the Age of BLood Evaluation
(ABLE) trial (and other trials conducted over a similar time period) there was no high-quality clinical research
to determine whether or not older stored RBCs deliver oxygen to tissues as effectively as fresher RBCs.
Current standards for approval of RBC products are based on characteristics of the product, especially RBC
survival in vivo at 24 hours, but not the ability of cells to transport oxygen to tissues. Prior to the ABLE trial,
an accumulating body of laboratory and clinical research had raised the possibility that stored RBCs may
be ineffective or even have harmful effects on patients.5–8 None of this evidence was conclusive, but the
signals seen in some uncontrolled observational clinical studies, together with the widespread use of RBC
transfusions, meant that this research question was of vital importance to ensure that RBCs are used safely
and effectively in the future. The implications of differences in effectiveness and safety of older versus
fresher blood also have major practical and financial implications for blood services.
Transfusion laboratories actively manage RBC supplies to minimise wastage, because RBCs are a precious,
limited and increasingly costly resource. As a result, RBCs stored for longer periods are frequently supplied
to users, and older RBCs tend to be used first. RBCs are used for a wide range of patient groups as part of
the management of a wide range of diseases and their complications. Importantly, indications for RBC
transfusion range from life-threatening haemorrhage (e.g. trauma, gastrointestinal bleeding, postpartum
haemorrhage) to the management of anaemia in otherwise stable patients (e.g. chronic inflammatory
conditions, cancer and postoperative anaemia). Remarkably, prior to the ABLE trial, there was no
high-quality evidence to reassure clinicians, blood services and patients that RBCs of all licensed storage
ages are equally effective for any of these patient groups or clinical indications.
A systematic review undertaken in 2006 found only two small RCTs in adults relating to RBC transfusion.8–10
Both trials were undertaken by members of the ABLE Canada or ABLE UK study groups. One was a study
with physiological end points and the other was the feasibility study for the full ABLE trial. Neither provided
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conclusive information about the effectiveness and safety of stored blood in comparison with a fresher
product (in total, only 89 patients were included).
Why were critically ill patients a suitable population in whom to study
this question?
There was a strong rationale for undertaking research to assess the clinical effectiveness and safety of older
versus fresher RBCs in critically ill patients. First, anaemia is very common and up to 95% of patients in
intensive care units (ICUs) have haemoglobin values below the normal range after 2–3 days.11,12 Second,
RBC transfusion is one of the most common therapeutic interventions in the ICU;11 30–50% of all patients
receive at least one RBC transfusion during their ICU stay, and a significant number receive RBC transfusions
during the pre- and post-ICU hospital stay; in the UK, 10% of all RBCs are transfused to patients in general
ICUs.13 Third, there is strong evidence from a previous landmark trial [the Transfusion Requirements in
Critical Care (TRICC) trial]14 that a restrictive haemoglobin transfusion trigger is safe for most critically ill
patients. As a result, the use of RBCs is more consistent in the critically ill, which decreases the potential
confounding effect of wide variation in RBC use among similar patient groups. Fourth, the need to improve
the evidence base for RBC transfusion in critical care is widely supported by clinicians. A research priority-
setting exercise undertaken by the UK Intensive Care Society had identified this research topic among active
ICU clinicians as an area of urgent need and importance for further research. This led to a research topic
proposal to the Health Technology Assessment (HTA) programme, submitted by the Intensive Care Society
on behalf of the clinical community. These factors also indicated a willingness from the clinical community to
participate in the ABLE trial in the UK. Fifth, the rationale for RBC transfusion is to restore oxygen-carrying
capacity. Critically ill patients frequently have an oxygen supply–demand imbalance, so the biological
plausibility of a difference in effectiveness between fresher and older stored RBCs was high. Sixth, mortality
from critical illness is high, typically between 20% and 25% in UK ICUs, so this question was of particular
relevance to this patient population. The incidence of morbidity that is potentially related to RBC transfusion
(e.g. organ failures and infections) is also high, making these useful secondary outcomes. Seventh, critical
illness is associated with high health-care costs over a prolonged period, and patients suffer significant
long-term disability and reduced health-related quality of life (HRQoL).15 This is therefore an appropriate
population in which to assess cost-effectiveness of this intervention. Eighth, critically ill patients are cared for
in dedicated ICUs with specialist staff experienced in the use of RBCs and undertaking complex research
protocols, which meant that a trial was feasible and likely to be relatively efficient.
Changes to red blood cells during storage
Several reviews have summarised a large volume of literature characterising well-defined biochemical and
cellular changes to RBCs during storage, collectively referred to as the storage lesion.6,8,16 During storage,
RBCs undergo a predictable change in structure, evolving from biconcave discs to spheroechinocytes. These
changes are associated with a number of biochemical and biomechanical changes, including a depletion of
adenosine triphosphate and 2,3-diphosphoglycerate (2,3-DPG), membrane phospholipid vesiculation and
loss, protein oxidation, lipid peroxidation of cell membranes and loss of deformability. It is biologically highly
plausible that these changes may have adverse clinical consequences by diminishing oxygen transport
through capillary networks. Specifically, structural changes and the loss of cell deformability impair the
ability of 8-µm RBCs to navigate the capillary networks, which typically have a smaller diameter. Even if
RBCs are able to navigate capillaries, the depletion of 2,3-DPG in the stored RBCs may impair their ability to
release oxygen to cells and tissues. Transfusing 2,3-DPG-depleted RBCs in primates, including humans,
depletes systemic 2,3-DPG levels and shifts the oxygen dissociation curve leftwards, changes that require
24 hours to several days to reverse. Normal circulating RBCs also facilitate capillary transit by releasing nitric
oxide, and this physiological effect is rapidly lost during storage.
SUMMARY OF TRIAL RATIONALE, EXISTING EVIDENCE, HISTORY OF APPLICATION (INTERNATIONAL COLLABORATION)
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The described changes occur at different rates over time, and can be modified but not eliminated with the
use of storage solutions. Alterations are well established by 18–21 days, which is the typical age of RBCs
currently transfused in the UK and other countries as standard practice.17–19 At present, the standard used
by blood providers to determine storage duration is that 75% of transfused RBCs should survive in the
circulation 24 hours after transfusion. This is clearly not a measure of clinical or physiological effectiveness,
but rather of physical survival. These measurements are also undertaken in relatively healthy individuals,
whereas critically ill patients have an abnormal microcirculation that could further accentuate the clinical
importance of the storage lesion.
Prolonged RBC storage changes the supernatant as well as the RBC. In the suspension medium, studies
have noted the generation of cytokines and other bioactive substances, including histamine, complement,
lipids and cytokines.8,16 These bioactive substances may stimulate proinflammatory pathways and perhaps
change flow patterns in the microcirculation. Other well-documented time-dependent changes include a
progressive fall in pH, an increase in plasma potassium levels and release of free haemoglobin from
lysed RBCs.
A further relevant factor relates to the use of leuco-reduced prior to storage in the blood bank. In the UK,
since 1999, all RBC products must be leuco-reduced prior to storage. This was introduced to minimise the
risk of variant Creutzfeldt–Jakob disease transmission, but a substantial body of evidence suggests that this
may alter the nature and severity of the storage lesion. In general, evidence would suggest that the storage
lesion, based on laboratory assays, is reduced by removing leucocytes from the RBC bag. A substantial
proportion of the published observational literature relating to RBC storage and clinical outcomes used
populations in which non-leuco-reduced RBCs were used. The generalisability of this literature to the current
product was also questionable. Despite this, many countries, including Canada, where the ABLE trial was
initiated, have introduced universal leuco-reduced.
In summary, prior to the ABLE trial there was substantial evidence that biochemical and structural changes
during storage could decrease the ability of RBCs to transport and release oxygen through effects on
oxygen uptake and release, and the process of capillary transit and storage-related accumulation of
substances in the supernatant could have adverse clinical effects.
Animal evidence relating to red blood cell storage
Prior to the ABLE trial, animal models had been developed and used to test transfusion efficacy. Earlier
studies demonstrated that old stored rat blood did not improve tissue oxygen consumption as compared with
fresh RBCs.20 By bleeding animals and replacing blood with RBC-free solutions (isovolaemic haemodilution),
haemoglobin concentrations were so low that each RBC transfusion should result in increased uptake of
oxygen by cells (a supply-dependent state). If RBCs worked properly in the supply-dependent state, there
should be a noticeable decrease in serum lactate levels and an increase in oxygen consumption. Using this
model, studies consistently noted that the transfusion of rat RBCs stored under standard conditions for
28 days when compared with fresh RBCs (stored for < 5 days) did not consistently improve measures of tissue
oxygen consumption or hypoxia. However, it had subsequently been shown that these observations were in
part explained by low post-transfusion survival of stored rat RBCs, but the experiments demonstrate the
potentially limited efficacy of stored RBCs.20,21 In the most comprehensive animal study, Raat et al.22 compared
the transfusion of 2- to 6-day-old, 2- to 3-week-old and 5- to 6-week-old human blood in a rat isovolaemic
exchange model, and showed a decrease in microvascular partial pressure of oxygen in the gut with older
RBCs compared with fresh and intermediate blood. However, these changes were not marked, and their
clinical relevance to human disease was uncertain.
In summary, animal studies provided some evidence that older RBCs had lower efficacy to transport
oxygen than fresh RBCs, but did not allow any conclusion regarding the clinical importance of these
effects in humans to be made. The limitations of animal models to human disease supported the need
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for adequately powered effectiveness trials in a relevant human population, with clinically relevant
outcome measures.
Clinical studies examining the importance of the red blood cell
storage lesion
Cohort studies
Prior to the ABLE trial, a number of retrospective clinical studies had examined the association between
prolonged storage times and adverse clinical outcomes. These had been reviewed shortly before the trial
began.16 These studies showed variable associations between storage age of RBCs and a wide range of
adverse clinical outcomes, including mortality, pneumonia, serious infections, multiorgan failure and length
of stay in many patient populations, including multiple-trauma victims, critically ill patients and patients
undergoing cardiac surgical procedures. Associations between RBC storage age and adverse outcomes
were not consistent across these studies, and the effect size observed among positive studies was also
highly variable. The cohort study with the highest impact originated from a single-centre US cardiac study.
Koch et al.23 undertook a retrospective review of a cardiac surgery database and compared large cohorts
that received either all RBCs stored for < 15 days (2872 patients) or all RBCs stored for ≥ 15 days (3130
patients). In adjusted analyses, the authors found strong associations between transfusion of older RBCs
and excess in-hospital mortality, plus a range of other adverse patient outcomes (including renal failure
and infection), which persisted 1 year after surgery. A major criticism of this study was that more patients
in the cohort receiving older RBCs required massive transfusion (> 6 units of RBCs), which is known to be a
strong predictor of adverse outcomes. The interpretation of cohort studies exploring the relationship
between RBC transfusions and patient outcomes is notoriously difficult because of multiple forms of bias,
including confounding by indication, variation in RBC exposure, residual confounding from unmeasured
clinical factors (especially in complex populations such as the critically ill) and differences in the local
RBC product used (especially leuco-reduced vs. non-leuco-reduced RBCs). These issues are particularly
problematic when the effect of RBC storage duration is explored, because it is impossible to separate the
known association between greater RBC exposure and adverse outcomes from the greater chance of
receiving older RBCs when larger transfusions are required.24 The confusing observational literature in this
area was at best hypothesis-generating, and further justified the need for controlled trials with the current
RBC product. The study by Koch et al.,23 although inconclusive, substantially increased the importance of
this question to clinicians, notably in cardiac surgery patients. The ABLE trial did not include patients
undergoing uncomplicated cardiac surgery, but the importance of the question to this population was
recognised in a trial undertaken concurrently with ABLE, RECESS (REd CEll Storage duration Study;
NCT00991341).
Randomised controlled trials
Two RCTs in adults had been reported in the literature prior to commencing the ABLE trial. In a double-blind
randomised trial, Walsh et al.9 evaluated changes in gastric perfusion and oxygenation in 22 mechanically
ventilated, critically ill patients who required a RBC transfusion in the absence of haemorrhage. The authors
were not able to detect any adverse effects of older leuco-reduced RBCs (all units stored for > 20 days) on
gastric intramucosal pH or arterial–gastric mucosal carbon dioxide gap when compared with fresh RBC
transfusions (all units stored for < 5 days) or with baseline pre-transfusion values. These results contradicted
a highly cited, uncontrolled observational before-and-after study conducted by Marik and Sibbald,25 who
found an inverse relationship between the age of transfused red blood cells and gastric intramucosal pH
(r = –0.71; p < 0.001), suggesting that older RBCs might reduce gastric perfusion and oxygenation.
The second RCT was a pilot study undertaken in Canada (by the ABLE trial investigators), which aimed to
establish the feasibility of undertaking a large RCT comparing standard storage age RBC transfusions with
exclusive use of RBC transfusions stored for ≤ 7 days.10 From the 57 patients included in the analysis, the
median storage time was 4 days in the experimental group compared with 19 days in the group allocated to
receive standard-aged blood [a difference of 15 days, interquartile range (IQR) of 12–16 days; p < 0.001].
Overall, 91% of patients allocated to receive fresh blood received RBCs with storage times of ≤ 7 days.
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There were important prognostic imbalances favouring the control group, including age and comorbidities,
but no major differences in clinical outcomes or adverse events (AEs) were found. Key learning points from
this study included a greater understanding of the RBC inventory processes required, the benefit of a run-in
phase in each centre, the process of blinding RBC storage age from clinicians and the benefit of deferred
consent at the time of the first transfusion decision.
Proposed mechanisms linking the red blood cell storage lesion with adverse
clinical outcomes
Evidence is emerging that shows two general mechanisms could link prolonged RBC storage with adverse
clinical outcomes, such as (1) an impaired ability of stored RBCs to transport or deliver oxygen effectively to
tissues and (2) stimulation of the inflammatory cascade. A common end point of both mechanisms is organ
failure, which is strongly associated with increased mortality during critical illness. RBC transfusion may
trigger or worsen the systemic inflammatory response syndrome as one of the ‘multiple hits’ that typically
occur during critical illness. Evidence of a direct pro-inflammatory effect from RBC transfusion could be
explained by the many pro-inflammatory molecules detectable in RBC units.8 Altered immune cell function
post transfusion has been recognised for many years, and may predispose patients to further sepsis,
especially nosocomial infections. Changes to RBC membrane composition, deformability and possibly nitric
oxide release following prolonged storage may result in endothelial interactions that increase thrombosis,
vasoconstriction and leucocyte adhesion, resulting in impaired flow, ischaemia and inflammation. Pre-storage
leuco-reduction of RBC units may abrogate some of these storage effects, but it is unproven if they become
clinically unimportant. A large before-and-after trial evaluating the impact of a universal pre-storage
leuco-reduction programme found that rates of febrile episodes were reduced and a small (1%) mortality
reduction occurred, but there was no change to infection rates.26 Meta-analyses of trials of leuco-reduction
have equivocal conclusions and do not uniformly indicate improved clinical outcomes with leuco-reduced
blood. Therefore, although universal pre-storage leuco-reduction, which has been mandated since 1999 in
the UK, has changed the standard RBC product, there is insufficient evidence to assume that this means that
stored RBCs have identical effectiveness and safety compared with a fresher product.
Conclusions and summary of background in relation to existing research
Prior to the ABLE trial, the need for a trial was justified by a range of issues: (1) strong animal and laboratory
evidence supporting the hypothesis that prolonged storage decreases RBC efficacy as an oxygen transporter
and could result in deleterious clinical effects through inflammatory mechanisms; (2) observational studies
in human populations reporting a number of associations between prolonged RBC storage and adverse
clinical outcomes, including mortality and organ failure, but a clear recognition that this research design
was inherently flawed by multiple forms of confounding and bias; and (3) the lack of completed or ongoing
adequately powered trials addressing this question. In addition, the widespread use of RBCs in health care
generally, and transfusion rates of 30–50% among critically ill patients, justified the need for a large,
definitive trial to compare current RBC transfusion practice with exclusive use of fresher RBCs.
Context of the Age of BLood Evaluation trial in the UK
The importance of storage age of RBCs during critical illness was suggested as a topic to the National Institute
for Health Research (NIHR) HTA programme and processed through the prioritisation and commissioning
boards. Concurrently, the ABLE trial was funded and commenced recruitment in Canada, co-ordinated by the
Ottawa Health Sciences Centre and run by the Canadian Critical Care Trials Group. The UK chief investigator
(TSW) had been involved in the development and funding of the Canadian grant, but funding did not permit
set-up of UK sites. The NIHR HTA programme commissioned a proposal for a UK arm of the ABLE trial through
the UK Intensive Care Society, harmonised with the Canadian trial protocol, to ensure the proposed sample
size was achieved. The UK proposal included a health economic evaluation, which was unique to the UK
arm of the trial. This comprised a cost–utility analysis of fresh blood versus standard-aged blood and a
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methodological substudy to compare different versions of the EuroQol-5 Dimensions (EQ-5D) HRQoL measure
in critical care patients. In addition, given the results of the primary analysis, a further substudy was
subsequently added (following agreement with the funder) using the health economic data to evaluate factors
associated with costs and quality-adjusted life-years (QALYs) in UK ABLE trial patients. Around the same time
that the UK arm of the trial was funded, funding was obtained to extend recruitment to the Netherlands and
France such that the ABLE trial became an international critical care trial supported by multiple funders and
trial networks, but working to a single sample size and clinical trial protocol.
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Chapter 2 Trial design and protocol
Objectives
Primary objective
The primary objective of the international ABLE trial was to answer the following research question.
In critically ill adult patients requiring RBC transfusion, does transfusing fresher RBCs stored for ≤ 7 days
compared with standard-issue RBCs stored for up to 35 days decrease mortality, organ failures and
new infections?
Secondary objectives
For the UK ABLE study, several additional objectives were defined.
1. To establish if, in critically ill adult patients, the use of RBCs stored for ≤ 7 days compared with
standard-issue RBCs stored for up to 35 days improves HRQoL.
2. To establish the cost-effectiveness of transfusion using RBCs stored for ≤ 7 days compared with
standard-issue RBCs stored for up to 35 days.
Study end points
Primary end point
Ninety-day all-cause mortality.
Secondary end points
1. Intensive care unit and hospital mortality; 28-day, and 6- and 12-month mortality; survival times.
2. Number of organ failures developing; multiple organ dysfunction score; time to development of organ
failure; highest number of organ failures per patient.
3. New infections (including nosocomial pneumonia, deep-tissue infections and bacteraemia).
4. Duration of respiratory, haemodynamic and renal support.
5. Length of hospital and ICU stay.
6. Adverse event rates, including transfusion reactions.
7. Health-related quality of life at 6 and 12 months, measured using the EQ-5D.
Study design
The ABLE study was an international double-blind, multicentre, randomised clinical trial. A summary flow
diagram describing the trial is shown in Figure 1.
Patients were randomised to one of two groups, receiving either:
1. standard-issue RBCs (average storage age: 18–21 days)
2. red blood cells stored for ≤ 7 days (average storage age: 2–7 days).
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Following randomisation, all decisions about when to transfuse were determined by caring clinicians
unaware of group allocation, and there was no protocol for transfusion decision-making in the trial.
The transfusion practice was, therefore, considered to represent current practice in terms of timing,
triggers for transfusion and transfusion volumes. The only difference in treatment between the groups
was, therefore, the storage age of RBCs used, with both groups receiving currently licensed RBC product.
There were no additional blood samples or procedures beyond routine care, and all follow-up data were
gathered from the patient record or from questionnaire-based follow-up.
All admissions to participating
ICUs screened for eligibility
if decision to administer RBC transfusion
made by responsible clinician
If eligible, seek consent/assent from NOK/welfare
attorney/doctor (according to English or Scottish
mental capacity legislation)
Consent for inclusion given?
Excluded
Reasons for
exclusion recorded
Yes
Consent declined
Transfused fresh RBCs
whenever transfusion required
(storage for ≤ 7 days)
• Received fresh RBCs
   throughout hospital stay
• Did not receive fresh RBCs
   throughout hospital stay 
   (give reasons)
Transfused standard
RBCs whenever
transfusion required
(standard blood bank issue)
End of intervention (maximum 90 days)
Allocation
Screening
Hospital
discharge
90 days
post randomisation
6 and 12 months
post randomisation
• Follow-up complete
• Lost to follow-up (reasons)
• Follow-up complete 
• Lost to follow-up (reasons)
• Follow-up complete
• Lost to follow-up (reasons)
• Follow-up complete
• Lost to follow-up (reasons)
In
te
rv
en
ti
o
n
Outcome data
collection
• Mortality
• ICU organ failures
• Infections
• ICU, hospital stay
• Mortality
• HRQoL (EQ-5D)
• Resource use
FIGURE 1 The design of the ABLE trial in the UK. NOK, next of kin.
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Participant identification and selection
Study population
The ABLE trial population comprised a heterogeneous group of critically ill patients who received at least one
RBC unit during the critical care phase of their illness. Only pre-storage leuco-reduced RBCs were used,
because this is the standard-aged blood product in the UK and Canada, and most other health-care systems.
Inclusion criteria
All admissions to the ICU were potentially eligible for up to 7 days following admission and were tracked
using screening logs for the following:
1. The patient had a request for a first RBC unit transfusion in the ICU.
2. The patient had an anticipated length of invasive and/or non-invasive mechanical ventilation (MV)
of ≥ 48 hours once enrolled, as estimated by the attending physician.
Exclusion criteria
Exclusion criteria were classified into clinical criteria and transfusion laboratory criteria.
Clinical criteria
1. Patients who were aged < 16 years.
2. Patients who were previously enrolled in the ABLE trial.
3. Patients who had already been transfused with RBCs during the current hospitalisation.
4. Patients who had an obvious terminal illness documented in the medical record with a life expectancy
of < 3 months.
5. Patients who had undergone routine cardiac surgical care (the proposed UK study would not take place
in cardiac surgery ICUs).
6. Patients in whom a decision to withdraw/withhold critical care had been made (including patients with
probable or proven brain death).
Transfusion laboratory criteria
1. No RBCs with a storage time of ≤ 7 days were available in the transfusion laboratory or could not be
supplied for other reasons at the time of eligibility and potential randomisation.
2. Patients who required urgent transfusion of > 1 unit of uncross-matched RBCs.
3. Patients who had a known objection to blood transfusions.
4. Patients who planned to receive autologous-donated RBCs.
5. Patients who posed difficulties in securing blood products (i.e. those who had rare blood groups),
and who were difficult to match.
Screening for eligibility
Patients eligible for the ABLE trial were identified by clinicians ordering RBC transfusion and via regular
screening by research assistants/nurses. Screening logs tracking all patients admitted to the ICU who had
not received a RBC transfusion were maintained by research staff to maximise recruitment potential.
Reasons for non-enrolment were captured to understand barriers to enrolment and to implement
strategies to improve recruitment rates.
Consent
Most patients were incapacitated at the time of eligibility (critical illness, MV or sedation), such that the
Mental Capacity Act 200527 and Adults with Incapacity (Scotland) Act 200028 provided guidance. Because
transfusion is usually a time-critical intervention, excessive delays in transfusion that were directly attributable
to the trial could result in an enrolment bias by clinicians. In practice, the decision to enter the trial needed to
be made within 1–2 hours in most cases (or sooner in cases with bleeding). Several approaches to obtaining
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consent were used, depending on the urgency of transfusion, mental capacity of the patient and availability
of relatives. In addition, the different laws relating to research in incapacitated patients in Scotland versus
the remainder of the UK influenced the processes.
l Patients considered to have mental capacity were approached directly, and their informed
consent requested.
l For patients who lacked capacity, the approaches differed between Scottish and English/Northern Irish sites
in accordance with local legislation regarding the inclusion of incapacitated patients in medical research.
This also arose because the ABLE trial was not considered to be a clinical trial of an investigational
medicinal product. As such, the laws governing consent differed between UK countries.
In addition, patients who survived their illness and regained capacity were approached for consent to
remain in the trial. The processes used, which reflected the differences in law between England/Northern
Ireland and Scotland, are summarised in Figures 2 and 3.
Randomisation
Group allocation
Group allocation was concealed from clinicians and researchers involved in care of the patients in the
ICU. Randomisation was undertaken by research staff within the participating ICUs, in accordance with
individual site arrangements via the ABLE trial web-based randomised system based in the Ottawa Health
Research Centre, modified for UK centres. However, the group allocation was restricted to the hospital
transfusion laboratory in order to maintain blinding of clinical and research teams in the ICU. Following
randomisation, group allocation was concealed from research and clinical staff throughout the intervention
period and follow-up, and was only known to transfusion laboratory staff.
Yes
Approach patient and
use participant
pre-randomisation
information sheet and
consent form
Does the patient have
mental capacity in
relation to the study?
No
NoYes
Approach relative/WA in
person. Use relative/WA
information sheet and
consent form
Seek telephone consent
using verbal explanation
guide and verbal
consent form Patient regains capacity.
Use participant 
post-randomisation 
information sheet and 
consent form
Approach relative/WA at
earliest opportunity. Use
relative/WA information
sheet and consent form
Does the clinician consider the blood
transfusion can be delayed until
relative/WA is approached
in person?
FIGURE 2 Consent flow chart used to determine the appropriate method for obtaining consent in Scotland.
WA, welfare attorney.
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Allocation was stratified by trauma versus other critically ill patients, and by study centre. The randomisation
process comprised computer-generated random listing of the treatment allocations using a pre-established
minimisation algorithm. Randomisation in the UK used the existing Canadian ABLE trial randomisation
system modified to include UK centres. Only the study statistician and designate at the co-ordinating centre
had knowledge of the randomisation codes.
Concealment following group allocation
All RBC units issued to patients had the expiry date (and date bled) concealed by application of an adhesive
label by the transfusion laboratory technician/biomedical scientist prior to issue to patients. Accompanying
documentation also had any expiry dates obscured. After the expiry date was obscured, the donations had a
luggage label attached identifying the unit as part of the trial. The hospital transfusion laboratory completed
full documentation to ensure that the expiry date of the product had been recorded and checked prior to
issue. These procedures were all approved and carried out according to agreed standard operating
procedures (SOPs) in each participating transfusion laboratory.
Protection against sources of bias
The following steps were undertaken to minimise the chance of bias: (1) concealment of randomisation;
(2) masking of intervention; (3) maintaining a screening log at each centre to record the number of patients
screened, number not randomised and the reason for exclusion, which enabled a comparison of the
characteristics of ABLE trial patients with all eligible patients; (4) blinding of ICU staff from group allocation;
(5) the Data and Safety Monitoring Committee (DSMC) and executive committee remained masked from
group allocation throughout the trial, by using a designated statistician to prepare all randomisation
schemes and interim analyses; and (6) adjustment for major co-interventions – potentially relevant major
co-interventions, such as the use of all blood products, MV and vasoactive drugs that may influence oxygen
transport, were recorded prospectively.
Yes
Approach patient and
use pre-randomisation
information sheet and
consent form
Does the patient have
mental capacity in
relation to the study?
No
NoYes
Approach personal consultee
with pre-randomisation
information sheet and
request completion of personal
consultee declaration form
Seek agreement from doctor
independent of study and
request completion of
clinician agreement form
Approach personal consultee at earliest
opportunity (if patient remains incapacitated) with
post-randomisation information sheet and request
completion of personal consultee declaration form
Does the clinician consider that the
blood transfusion can be delayed
until personal consultee is
approached?
Approach patient for 
consent at earliest 
opportunity after they 
regain capacity with 
participant 
post-randomisation 
information sheet and 
consent form
FIGURE 3 Consent flow chart used to determine the appropriate method for obtaining consent in England and
Northern Ireland.
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In the UK, an audit was also undertaken of a sample of all sequential ICU admissions to participating ICUs
in which RBC use was collected to enable an assessment of how the enrolled cohort compared with all
ICU patients receiving RBCs during hospitalisation.
Management and data collection during the intervention
Baseline data collection
Baseline data included age, sex, hospital and ICU admission dates, type of admission, most responsible ICU
admission diagnosis, Acute Physiology and Chronic Health Evaluation II (APACHE II) score at ICU admission,
transfusion history during the 4 weeks prior to admission and significant comorbidities. Co-interventions
administered at randomisation were recorded, including MV, dialysis/renal replacement therapy and
cardiovascular support.
Transfusion decisions during the intervention period
All RBC units were prepared in accordance with international standards, and, in the UK, represented usual
practice. There was no control over transfusion decisions, which were at the discretion of the caring clinician.
Duration of the intervention
The intervention was intended to last from randomisation to hospital discharge, death or 90 days post
randomisation, whichever occurred soonest.
Appropriate allocation of red blood cells to patients
The conduct of the study was reliant on the operation of the individual transfusion laboratories with
respect to the administration of appropriately aged RBCs to patients in the two trial arms, whenever they
were requested by clinicians during the intervention period.
Issue of red blood cells
All requests for RBC units were processed and blood issued according to standard local protocols. All
participating ICUs utilised existing blood stock management, which usually involved issuing RBCs closest to
expiry to minimise wastage. Blood banks that provided fresh RBCs to critically ill patients as a routine were
not included in the trial. All patients enrolled in the study had their randomisation allocation ‘flagged’ in
the local laboratory information management system.
Masking of expiry
To ‘blind’ the true expiry date of the RBC units from clinical staff, the following changes to the standard
processing of RBC units were made once the unit was ready for issue to a named patient: (1) the transfusion
laboratory technician/biomedical scientist covered the expiry date (and date bled) on the blood unit label
with an ‘ABLE trial sticker’, and blacked out the expiry date on the hospital cross-match compatibility tag
and the issue sheet (and any other accompanying documentation that had the true expiry date of the unit);
(2) a separate label was attached to the RBC unit, advising that the patient was on the ABLE trial and that
the expiry date had been shortened, using the wording ‘This unit of blood has been issued for transfusion to
a patient on the ABLE (Age of Blood) Study. It must be transfused by 23:59 hrs on D/M/Y** or returned to
hospital transfusion laboratory. The unit must be transfused within 4 hours of removal from blood fridge’;
and (3) the unit of blood was then issued and collected following standard local procedures.
Checking/administration of red blood cell units in clinical area
Checking procedures were controlled locally according to SOPs consistent with national recommendations.
Monitoring of patients during transfusion followed local agreed policies. Each unit of blood was transfused
within 4 hours of removal from the satellite blood fridge/temperature-controlled storage as per national
recommendations. All documentation was completed according to local protocols, including signing and
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recording the donor component number on transfusion documentation. Traceability documentation was
completed and followed as per local policy.
Recording co-interventions during the follow-up period
All blood components received during the follow-up period for up to 90 days post randomisation were
recorded, including plasma, cryoprecipitate and platelets. Immunoglobulin, albumin and other relevant
blood products, including recombinant factor VIIa and prothrombin complex, and receipt of starch
solutions were also recorded.
Recording of clinically relevant complications during intensive care unit and hospital
follow-up
Patient complications
The occurrence and date of onset of a range of clinically relevant complications were recorded for the
period from randomisation to ICU discharge. These complications comprised:
l acute lung injury and acute respiratory distress syndrome
l pulmonary oedema
l cardiovascular failure, cardiac ischaemia or infarction or cardiac arrest
l deep-vein thrombosis or pulmonary embolism
l acute transfusion reaction
l severe sepsis or septic shock
l multiple organ dysfunction syndrome (MODS)
l infections (pneumonia, surgical site infection, bacteraemia, urinary tract infection or other infections)
l other important outcomes (specified by the investigator).
For the remainder of the intervention period after ICU discharge, additional complications were reported as
AEs at the discretion of the local principal investigator. All transfusion reactions occurring during the trial
were reported as serious adverse blood reactions and events and serious hazards of transfusion in
accordance with usual standard reporting practices in the NHS.
Recording of other important patient data during intensive care unit and hospital
follow-up
Duration of organ support
The duration of ventilatory support, cardiovascular support and renal replacement therapy was recorded.
Change in organ dysfunction
Data to calculate the MODS score were recorded on a daily basis from day 1 to 7 post randomisation and
then every 7 days until ICU discharge, death or 90 days, whichever was sooner. Haemoglobin concentration
was also recorded at the same time points, when available.
Level of care
For the health economic analysis the total days of ICU (level 3), high dependency (level 2) and other
ward-based care were recorded for the entire index hospital stay.
Follow-up
In the UK, the duration of follow-up extended to 12 months post randomisation, or until a participant died
or withdrew from the trial. This duration was longer than for the other international sites, where follow-up
for 6 months was undertaken. The longer UK follow-up was undertaken for the health economic analysis.
DOI: 10.3310/hta21620 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 62
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Walsh et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
13
Follow-up during intensive care unit stay and subsequent hospital stay
Follow-up data during ICU stay and remaining hospitalisation were from the patient charts, records and
laboratory databases. No study-specific tests, such as additional blood samples or investigations, were
required. While in the ICU, daily recording of measures of organ failure and support measures was
undertaken for the first 7 days and weekly thereafter, until ICU discharge, up to a maximum of 90 days.
Data on hospital mortality and date of hospital discharge were collected from hospital statistics and/or
hospital charts.
Follow-up following hospital discharge, including long-term follow-up
Ninety-day survival status
Ninety-day all-cause mortality was ascertained through hospital records for patients who died in hospital.
Prior to any contact with surviving patients after discharge from hospital, the patient’s general practitioner
(GP) was contacted to confirm their status.
Six-month follow-up
Patients were contacted according to a SOP at 6 months (± 4 weeks). After establishing/confirming survival
status with the patient’s GP, the questionnaire-based follow-up included the following measures.
l The EQ-5D29 HRQoL questionnaire. To enable a methodological substudy comparing the EQ-5D
versions (see Chapter 6), patients at half of the UK sites received the EQ-5D, three-level version
(EQ-5D-3L), and the remaining patients received the EQ-5D, five-level version (EQ-5D-5L).30
l A health economic questionnaire. Participants were asked about health and social care resource use
retrospectively since hospital discharge. Resource-use items were: GP visits in the clinic and at home,
and telephone consultations; district and practice nurse visits; physiotherapist, occupational therapist
and speech and language therapist visits; dietitian, home care worker (e.g. ‘Meals on Wheels’), social
worker, psychological therapist, counsellor and aids and adaptation worker visits; specialist nurse
visits (substance misuse nurses, Macmillan Cancer Support nurses); day hospital visits; accident and
emergency (A&E) visits; outpatient appointments; and readmissions to hospital, including surgical
procedures and ICU spells.
l For patients admitted to the ICU with traumatic brain injury, the Extended Glasgow Outcome Scale
(GOSE) questionnaire was administered by telephone.
Initial contact was by post, with telephone contact being attempted in the event of non-response or
data queries.
Twelve-month follow-up
Patients were contacted at 12 months (± 4 weeks). After establishing survival status, a questionnaire-based
follow-up included the following measures.
l The EQ-5D HRQoL questionnaire (EQ-5D-3L and EQ-5D-5L), as at the 6-month follow-up; patients
received the same EQ-5D questionnaire version at both follow-up points.
l A health economic questionnaire. Resource items were the same as for the 6-month questionnaire,
covering the period from 6 to 12 months post discharge.
Initial contact was by post, with a second posting if questionnaires were not returned. Telephone contact
was attempted in the event of non-response or data queries. At both the 6- and 12-month time points,
a £5 gift voucher was sent with the follow-up questionnaires as a token of appreciation for involvement
in the study.
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Premature withdrawal of study participants
There were no predefined withdrawal criteria for patients following trial entry. We aimed to approach all
patients for consent to remain in the trial if consent/assent/non-objection for randomisation was provided
by a relative, welfare attorney, next of kin, personal consultee or independent clinician. For patients who
chose not to remain in the trial or who withdrew during the intervention or follow-up period, no further
contact was made. We asked these patients if they were happy for us to use data collected up to that
point and data that could be acquired without contacting or involving them further. If they requested
for all data to be removed, all data for that patient were destroyed. The same approach was used for
situations in which a relative, welfare attorney, next of kin or personal consultee requested withdrawal in
the absence of a mentally capacitated patient.
Statistical and data analysis
Sample size
The ABLE trial was designed to detect an absolute risk reduction in 90-day all-cause mortality of 5% from
25% to 20% (relative risk reduction of 20%). Justifications used in developing the trial in Canada were
that (1) the Trial Steering Committee [(TSC) which includes experienced critical care and transfusion
triallists and clinicians], international collaborators (which included the proposed chief investigator for the
UK study) and representatives of blood providers agreed that a 5% mortality difference would justify a
major change of the blood procurement and distribution system; (2) a subsequent survey of Canadian
intensivists indicated that clinicians thought that a study that documented a 5% improvement in 90-day
all-cause mortality with fresh blood compared with standard storage-age RBCs would justify a change in
the blood supply; (3) a 5% difference was a biologically plausible treatment effect based on the results of
the TRICC trial (in which different exposures to standard RBCs resulted in a trend to excess mortality in
liberally transfused critically ill patients) and some more recent cohort studies (notably a trial in cardiac
surgery patients);14,23 and (4) a baseline 90-day mortality of 25% was relevant to critical care patients who
required transfusion, and was expected in Canada and the UK based on available data.
For 80% power at a 5% significance level, the ABLE trial required to recruit 1133 patients per arm (a total
of 2266) to detect a 5% absolute risk reduction from baseline 90-day mortality of 25%. This total was
increased to 2510 patients (1255 per arm) assuming a non-compliance rate of 5%, which was consistent
with pre-trial pilot work. The UK sample size target was 500 at the time of funding.
Analyses
The analysis plan was developed by the international ABLE TSC, led by the Ottawa Health Research Centre.
Overall approach to analysis and baseline assessment
Baseline data of patients were assessed using frequency distributions and univariate descriptive statistics,
including measures of central tendency and dispersion. As this was an effectiveness trial, all statistical
analyses were based on an intention-to-treat approach. As a complementary approach, a treatment
received as per-protocol analysis of the primary outcome measure was also undertaken.
Analysis of primary outcome
The influence of treatment groups (fresh vs. standard-issue blood) on the primary outcome of 90-day
all-cause mortality was compared using chi-squared test procedures. Unadjusted but stratified relative
risks with 95% confidence intervals (CIs) for the primary comparison were calculated. Secondary analyses
using logistic regression models further elucidated the measure of effect while adjusting for possible
confounding variables. Independent covariates such as centre, age, sex and comorbid illnesses, and severity
of illness scores, were added to all logistic models. Pairs of variables were considered for inclusion into
logistic models if there was sufficient statistical evidence and the interaction had clinical rationale.
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Analysis of secondary outcomes
Treatment effects on other mortality rates such as ICU and hospital mortality as well as all-cause 6-month
mortality were calculated using relative risks followed by logistic regression procedures using comparable
models. We also compared Kaplan–Meier survival curves using a log-rank test followed by proportional
hazards modelling for all mortality rates. We compared rates of organ failure and infections using a
chi-squared test statistic. Finally, we compared processes of care, including length of hospital and ICU stay,
the length of time requiring respiratory, haemodynamic and renal support by using a Wilcoxon rank-sum
test statistic.
Co-interventions, compliance and losses to follow-up
A number of secondary analyses were conducted to better understand the influence of co-interventions,
compliance and losses to follow-up on the robustness of the intention-to-treat analysis. These included an
analysis of primary and secondary outcomes including only patients who completed the study as per
protocol, inclusion of co-interventions in all multivariate procedures and an ‘as-treated’ analysis comparing
all patients receiving all transfusions of ≤ 7 days storage age with those patients who received all
transfusions of > 7 days storage age, regardless of allocation.
The conduct of the trial and the safety of participants were overseen by the DSMC, the members of which
reviewed interim analyses after each consecutive group of 500 patients had been followed for 90 days.
We adopted the O’Brien–Fleming group sequential stopping rules for the four interim analyses. All data
management and statistical analyses were performed by the Methods Centre at the Ottawa Hospital
Research Institute. Clinical co-ordination was conducted by the Research Centre of Sainte-Justine Hospital
in Montreal.
Subgroup analyses
Using the approach outlined for primary and secondary analyses, similar steps for predefined subgroups of
patients were undertaken, including age, exposure to RBCs using 1–3 RBC units compared with > 3 RBC
units and an evaluation of severity of illness by comparing outcomes in patients with a low (< 20 points)
versus higher (≥ 20 points) APACHE II score. Comparisons by admission status (medical, surgical, trauma)
were also undertaken. These analyses were primarily hypothesis-generating or explanatory in nature.
UK analysis in the context of the international Age of BLood Evaluation trial
The protocol for the international ABLE trial was published.17 The end of the main trial occurred when the
predefined sample size was reached. This cohort was analysed, and the trial was published based on
follow-up data for up to 90 days (the primary end point).31 During recruitment, it was clear that the UK
target sample of 500 patients would not be achieved by the time that the international trial completed
recruitment. In order to acquire sufficient data to maximise the value of the economic evaluation, we
sought agreement from the international ABLE TSC, the funder (the NIHR HTA programme) and ethics
committees to continue recruitment in UK centres until the main database was locked for analysis. All
patients enrolled in the UK part of the trial were followed up for 12 months to collect data for the health
economic evaluation.
In this report, results from the prespecified analysis restricted to all patients enrolled in the UK cohort are
presented, and compared with the previously reported data from the full international ABLE trial.
Adverse events
Adverse events were expected to occur frequently among enrolled patients as a result of ongoing critical
illness. AEs that were expected in this population (i.e. events that are in keeping with the patient’s
underlying medical condition) were not reported as AEs. Congenital abnormalities/birth defects were not
relevant to this trial. Predefined clinically relevant complications recorded in the case report form, such as
organ failures and infections, were not additionally reported as AEs, with the exception of acute transfusion
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reactions. AEs related to blood transfusions were reported, including all acute transfusion reactions
occurring during the intervention period. This approach was used consistently across the international
recruiting centres.
Serious adverse events (SAEs) were expected in many of the participants, consistent with critical illness. SAEs
that were expected in this population (i.e. events that are in keeping with the patient’s underlying medical
condition) and those that were collected as outcomes of the trial, including death and organ failure, were
not reported as SAEs. Other SAEs were reported at the discretion of the research team at each site. The
period of reporting of SAEs by each site research team was from randomisation to 90 days following
randomisation for the index hospital admission or until hospital discharge, whichever was sooner.
Trial management and oversight
Trial Management Group
The ABLE UK trial was co-ordinated by a Trial Management Group (TMG), which comprised the UK
chief investigator (Timothy S Walsh; Critical Care Lead), the transfusion medicine lead investigator
(Simon Stanworth), the ABLE trial manager (Julia Boyd, Edinburgh Clinical Trials Unit), Douglas Watson
(Scottish National Blood Transfusion Service), Fiona Goddard (NHS Blood Transfusion), a critical care
co-ordinator (David Hope, Edinburgh), transfusion laboratory co-ordinators (Sue Hemmatapour and
Helen Burrows; Oxford) and the health economic lead (Helen Campbell, Oxford; replaced by Stephen Morris,
University College London, at a late stage in recruitment).
Trial Steering Committee
As the ABLE UK trial was part of the international trial, there was no separate TSC for the UK trial.
Timothy S Walsh, Simon Stanworth and Helen Campbell were members of the international ABLE TSC.
Data and Safety Monitoring Committee
As the ABLE UK trial was part of the international trial, we did not establish a separate DSMC for the
UK trial.
Membership of the international ABLE TSC and DSMC has been previously published.31
Ethics approvals
The study was conducted in accordance with the principles of the International Conference on Harmonisation
Tripartite Guideline for Good Clinical Practice. A favourable ethics opinion was obtained from the Scotland A
Research Ethics Committee (REC; 11/AL/0111) and the Oxford C REC (11/SC/0417). Local research and
development (R&D) approvals were obtained at all sites prior to commencing recruitment.
Amendments
Four amendments were made to the protocol during the study conduct (Table 1).
Patient and public involvement in research
As the ABLE trial was funded in the UK to participate in the international trial, we did not involve patients or the
public specifically in the UK project. Local patient representatives reviewed the study materials, specifically the
information sheets for participants and relatives, and provided feedback on clarity and presentation.
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TABLE 1 Summary of protocol amendments during the trial
Amendment
and date Summary of amendments
Amendment 1
September 2011 UK ABLE trial protocol submitted (original ethics approval was for the Canadian/international protocol).
Main differences between the Canadian and UK protocol reflected differences in the consent process in
the UK and differences in health service organisation. There were additional outcomes specific to the
UK, which included a HRQoL analysis and a health economic evaluation at 6 and 12 months. Various
questionnaires were also submitted: the EQ-5D, GOSE and health economic questionnaires at 6 and
12 months. Consent forms were also revised to allow access to the participant’s medical records for the
purposes of monitoring or inspections
Amendment 2
December 2011 Protocol revision: changes limited to section on consent – there were differing processes of consent in
Scotland and England/Northern Ireland reflecting the different legislation for adults with incapacity
Process of consent in Scotland: deferred consent removed from protocol. In cases in which the
participant was incapacitated, written or witnessed oral consent from the relative/welfare guardian
would need to be provided before the patient could be enrolled. The participant would always be
approached for follow-on consent when they regained capacity. These changes resulted in revised
consent forms and participant information sheets
Process of consent in England/Northern Ireland: changes made to the terminology to ensure
compliance with the Mental Capacity Act 2005.27 These changes resulted in revised consent forms and
participant information sheets
Two posters were also included in this amendment in order to raise study awareness: one for staff
areas and one for relative waiting areas
Amendment 3
March 2013 Protocol revision: changes to study recruitment timelines and targets – UK recruitment target lowered
to 400 participants, as the international study was recruiting ahead of schedule. It was agreed with the
Canadian TMG to continue recruitment in the UK for a further 180 days beyond recruitment of the last
participant in the international study. This enabled data from an estimated 100 additional participants
to be included in the main trial analysis report for primary outcome and facilitated approximately 100
additional cases to be enrolled in the UK-only health economic evaluation. The number of participating
UK sites was also increased and details of the TSC updated
Amendment 4
March 2014 Protocol revision: relating to patients recruited into the study who did not have capacity at the time of
enrolment. In these cases, patients were approached for consent at the earliest opportunity once
they regained capacity. In some cases, patients were discharged before the research team had the
opportunity to approach for consent. A process was added to the protocol to be followed in these
cases. Research teams should attempt to contact the patient after discharge as soon as was reasonably
practicable and provide them with information about the study and ascertain if they consented to
remain in the trial. Consent forms were also updated
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Chapter 3 Trial management, governance
and conduct
Approvals
The UK ABLE trial required a complex set of approvals to be in place to commence recruitment. These
reflected the international nature of the trial, the large number of centres involved, and the need to set up
both ICUs sand blood banks to enable randomisation and intervention management (Table 2). In total,
over 25 separate contracts/agreements were required to be set up and agreed between the sponsor’s legal
department and various organisations. This took considerable time and effort, and resulted in delays while
agreements were finalised.
One practical issue related to the definition of the UK protocol. The Canadian co-ordinating centre ran the
international trial and acted as sponsor for the Canadian sites, and a Canadian version of the protocol was
used. In the UK, with separate funding from the NIHR HTA programme to the University of Edinburgh, the
UK co-sponsors (University of Edinburgh and NHS Lothian) required a separate document representing the
UK protocol that was legally distinct from the Canadian protocol, despite the unification of protocols into
a single international trial. A separate UK protocol therefore needed to be written and approved by the
ethics committee.
TABLE 2 Summary of the range of contracts and approvals
Issues Solution
International agreements
Agreement to harmonise the Canadian and UK protocol and define data
ownership, publication rules, authorship and the right to utilise data
Legal agreement between the UK sponsor
(University of Edinburgh/NHS Lothian) and
Canadian lead site
Data sharing agreement to enable UK use of the relevant data in the
international data set
Separate data sharing agreement developed
between Canada, the University of Edinburgh
(sponsor) and University College London
(for the health economic evaluation)
UK agreements/contracts
Co-sponsorship agreement between the University of Edinburgh and NHS
Lothian
Legal agreement between organisations
Subcontracts between sponsoring site (University of Edinburgh) and
University of Oxford for health economic and blood bank co-ordinators
Legal agreements between institutions
Contracts with each of 20 participating sites Managed in waves, prioritising larger
higher-recruiting centres first
Contracts with other organisations receiving grant funding for the trial,
including NHS Blood and Transplant, the Scottish National Blood
Transfusion Service and the Intensive Care Foundation
Legal agreements with organisations
Ethics and R&D approvals
Scottish A REC for Scottish sites [Adults with Incapacity (Scotland)
Act 2000]28
–
English (Oxford) C REC (Mental Capacity Act 2005, England);27
incorporating approval for the site in Northern Ireland
–
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Ethics considerations
The different legal frameworks for incapacitated patients in England and Scotland required separate
ethics applications and approval processes, with trial materials using appropriate terminology for surrogate
decision-makers. In many international centres, a true waiver of consent was granted because the two
intervention groups were both part of standard care, and the decision to transfuse RBCs was determined by
clinicians and not in accordance with the trial protocol. In addition, delays to transfusion were considered
unacceptable, as these might have delayed treatment and reduced patient safety. UK law did not allow this
approach, but resulted in different approaches in England/Northern Ireland from those used in Scotland (see
Chapter 2). These differences made recruitment more difficult for some patients in Scotland, which adversely
affected recruitment rates. Approval of consent by telephone was important in Scotland to decrease this
impact. In all cases, the patient was approached wherever possible to obtain permission to continue in the
trial if they survived their ICU admission and regained capacity. This took considerable research nurse
resource and, in some cases, was difficult to achieve before patients were discharged home. The different
approaches required to obtain consent or lack of objection to participate and remain in the trial illustrate the
complex and time-consuming processes involved in trials recruiting critically ill, incapacitated patients with
time-sensitive recruitment windows and interventions.
Site set-up
Site set-up required both the clinical (in the ICUs) and blood bank teams to be trained and SOPs established
to execute the randomisation and group allocation. Blood bank set-up was challenging, but was facilitated by
specialist blood bank co-ordinators employed for the purpose of set-up, monitoring and support throughout
the trial. A detailed set of protocols and procedures was developed to enable potential participants to be
rapidly screened to ascertain if allocation to ‘fresh’ RBCs was feasible based on blood group, cross-match and
blood availability. In addition, procedures to ensure checking, blinding and modified blood issue procedures
were established. There were frequently delays in this set-up as a result of the intense pressure many NHS
blood banks worked under, and competing activities such as inspections and audits. A limited number of
technician staff were generally available to undertake randomisation and group allocation procedures, which
limited recruitment periods to weekdays in most centres. Despite dedicated funding for this activity, many
blood banks did not have access to additional staff to support the trial beyond routine NHS work. This
resulted in many potential participants being ‘missed’, and limited participation to mainly patients in whom
first RBC transfusions were prescribed during weekday working hours. In addition, procedures to ‘tag’
participants on local blood bank systems to ensure that subsequent requests for RBCs maintained both group
allocation and blinding were necessary, but did not delay blood issue. A modified blood-checking procedure
at the bedside by clinical staff that ensured that national standards were adhered to but that maintained the
blinding of RBC storage age was also needed in all centres.
Although the ABLE study was a trial based in the ICU, the major logistic challenges were in the blood
banks. This was the first large, multicentre UK trial that required multiple NHS blood banks to allocate trial
participants to receive different blood products under emergency conditions while maintaining blinding
from clinical teams. The success of the trial reflected very considerable effort and support by blood bank
staff and the blood bank co-ordinators working on the trial.
Timelines
A summary of the major trial set-up timelines is shown in Figure 4. We found a wide variation between
sites for times to R&D approvals, and times to recruitment of the first patient from final approval (Figure 5).
The reasons were multifactorial and varied between centres. Delays with final contracts between the
sponsor and study site were prevalent, as a result of the slow responses from legal teams. These resulted
in a ‘knock-on’ effect on final R&D approval; this was also delayed in some centres until clinical sites were
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FIGURE 4 Summary of the major logistic milestones during the set-up of the UK ABLE trial. CSP, Coordinated System for gaining NHS Permission.
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Site 80 Northampton General Hospital
Site 69 Norfolk and Norwich University Hospital
Site 68 Royal Berkshire Hospital, Reading
Site 67 Leeds St James’s University Hospital
Site 66 Leeds General Infirmary
Site 64 Edinburgh Western General Hospital
Site 63 Churchill Hospital, Oxford
Site 62 Newcastle Royal Victoria Infirmary
Site 61 Royal Victoria Hospital, Belfast
Site 60 Southampton General Hospital
Site 59 John Radcliffe Hospital, Oxford
Site 58 Freeman Hospital, Newcastle upon Tyne
Site 57 London Guy’s and St Thomas’ NHS FT
Site 56 Royal London Hospital
Site 55 King’s College London
Site 54 Leicester Royal Infirmary
Site 53 Bristol Royal Infirmary
Site 52 Heartlands Hospital, Birmingham
Site 51 Ninewells Hospital, Dundee
Site 50 Edinburgh Royal Infirmary
R&D approval
(number of days taken)
Day to first patient recruited
(from R&D approval date)
2498
7780
795
15022
17422
6747
28355
44764
40100
14827
21355
10864
13838
185 53
196 25
18837
26637
42 209
51 57
69 34
FIGURE 5 Summary of the time (days) for R&D approval and the time (days) from approval to first recruitment for the 20 ICUs that participated in the UK ABLE trial.
FT, foundation trust.
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ready to start screening, to minimise the impact of NIHR metrics that recorded time to first recruit. For
clinical set-up, delays in blood bank training were a major source of delay in some centres. Frequent
reasons were competing priorities, such as national inspections of the laboratory service (especially the
Medicines and Healthcare products Regulatory Agency), unrelated to the ABLE trial, and staff shortages
such that the organisational changes required to run the trial were delayed. The funding of dedicated
blood bank co-ordinators in the trial was vital to minimise these delays.
Trial management
A TMG met every 4–6 weeks throughout recruitment by teleconference. These meetings were
supplemented by regular investigator teleconferences with research staff (from both ICUs and blood
banks), at which representatives from all sites were encouraged to share both positive and negative
experiences of recruitment and trial conduct. These meetings were supplemented by regular newsletters
and recruitment tables circulated by e-mail. Screening logs were returned and examined in real time. This
was useful for a number of reasons: (1) it provided a rapid indication of when staffing or other problems
were affecting recruitment; and (2) it provided valuable data on the reasons that potential patients
were ‘missed’, which were collated and shared with all sites. This enabled a focus on solving common
recruitment problems that occur across all trial sites. For example, it rapidly became apparent that the
most common reason for missed recruitment was that the first transfusion took place out of hours when
research staff and/or blood bank staff were unavailable. Several ICUs used local audit to change their
practice and minimise night-time transfusions, consistent with current guidance.
These data enabled the reasons for non-enrolment of eligible patients to be clearly tracked during trial
conduct (Table 3) and were used to implement improvements in real time.
A continuously updated ‘top tips for recruitment’ checklist and sharing of solutions to problems was a
focus of these meetings, which maintained momentum. The ‘top tips’ checklist was used as an audit tool
to help each site explore whether or not they could optimise recruitment (Table 4).
TABLE 3 Reasons why eligible patients were not able to be considered for the UK ABLE trial based on screening
log information collected during the trial
Reasons why eligible patients were not randomised in the ABLE UK trial Number of patients
Insufficient time 97
Randomisation system N/A 1
Maximum number of locally active patients enrolled 1
RBCs needed urgently 5
Transfusion cancelled 2
Large-volume RBC transfusion 9
Transfused outside working hours 957
Transfused prior to screening completed 13
Transfused in operating theatre before randomisation 27
Other 167
Total 1279
N/A, not applicable.
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TABLE 4 The ‘top tips’ checklist that was developed during the trial based on regular engagement with
trial centres
Tip
Tick if in use at
your site
Study awareness
Include a talk on ABLE in induction for all new staff, especially junior medical staff. We have provided a
short presentation or a one-page summary of the trial that you can use
Distribute ABLE lanyards with contact numbers to all new staff. These include the entry criteria and can
have your contact details too
Ensure ABLE posters are on display (in staff areas and relatives’ room)
Mention ABLE in nursing and/or medical handovers, especially to highlight patients with low
haemoglobin concentrations or needing a transfusion during the shift
Add an ABLE sticker to daily charts, drug charts or other documentation for patients who are
potentially eligible for ABLE
Use electronic or white-board systems that are used to describe and track current patients, to highlight
patients potentially eligible for ABLE
Provide lists of potential ABLE patients to clinical staff prior to rounds
Screening
Try to screen twice per day (a.m. and p.m.) to catch new admissions
Try to join some clinical rounds to highlight potentially eligible ABLE patients
Encourage double-checking of blood gas haemoglobin values to minimise transfusion at night based
on blood gas measurements alone
Review screening logs regularly to explore missed patients. Particular cases to highlight are:
l Patients missed overnight . . . does the trainee know about ABLE?
l Patients prescribed blood without consultant input . . . was this consistent with unit policy and can
the episode be used to reduce unnecessary transfusions?
l Patients transfused at weekends . . . was this necessary? . . . could the patient have been included
in ABLE?
Feedback and incentives
Provide positive feedback and small prizes to any staff highlighting potential ABLE patients. ABLE pens
are a handy small token of appreciation; ask us if you require some more
Provide certificates for nurses, doctors or others who flag a potential ABLE patient or help to recruit a
patient. Suggest that these are included in continuing professional development or training files
(e.g. as an e-portfolio research item)
Reminder e-mails to clinical staff highlighting local recruitment, with thanks
Regular reminders to staff by e-mail regarding the ABLE enrolment criteria, why the study is important,
how it is going internationally and locally, how the unit is getting on in relation to recruited and missed
patients . . . can you highlight why patients are being missed?
Win–win strategies
Use ABLE screening as local audit data. Transfusions overnight should be avoided as a quality issue in
most hospitals. Feed back the number of overnight transfusions that were not urgent every month . . .
try to target reductions in these linked to consideration for ABLE
Feed back local transfusion data collected as ABLE screening to mortality and morbidity meetings,
quality improvement meetings, etc.
Engage trainees in performing local audits linked to ABLE screening
If you have local transfusion protocols . . . link ABLE screening data to audit against local protocols
to show compliance. Include audit against haemoglobin transfusion trigger, timing of transfusion
(day/night, etc.) and any other local protocol items
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Follow-up
A predefined strategy for follow-up at 6 and 12 months post randomisation was used. First, the patient’s
GP was contacted to ascertain survival status. Survivors were sent questionnaires by post, accompanied by
a £5 gift token. At 12 months, non-response to postal questionnaire was followed by a second postal
questionnaire. Failure to respond to postal follow-up was followed by up to three attempted contacts by
telephone to complete the questionnaires. In addition, any queries were resolved by telephone contact,
with up to three attempted contacts. As follow-up is known to be challenging in critical care survivors,
we collected data to summarise the total time needed to achieve follow-up data. We also analysed the
effectiveness of different approaches to follow-up in this population.
Audit data indicated that the average time required for each follow-up was 26 minutes at 6 months and
25 minutes at 12 months. Table 5 shows the success rate of the different follow-up strategies. Telephone
contact was attempted at least three times, and this significantly improved follow-up response rates,
especially at the 6-month time point.
TABLE 4 The ‘top tips’ checklist that was developed during the trial based on regular engagement with
trial centres (continued )
Tip
Tick if in use at
your site
For research staff
Reduce the number of patients being missed because they are transfused out of hours. Use strategies
that detect these, and feed them back in real time to clinical teams. Use them as an educational
opportunity for junior staff
Try to undertake individual case review of each missed patient to define why the patient was missed
and explore how this could be avoided . . . did it need education of a staff member about the trial?
Try to do this when the event occurred . . . it will be more effective!
Explore whether or not weekend recruitment may be feasible for clinical and blood bank teams. If it is,
let us know . . . we may be able to negotiate additional payments for weekend recruits
Can you identify patients who will be transfused in theatre prior to ICU admission and randomise them
pre-theatre? It is possible to randomise patients pre-theatre if RBCs have been requested by the surgical
or anaesthetic team. A flow chart and further information is included in the new protocol, which will
be distributed soon. Consider whether or not this could be done at your site
Ensure other teams are aware of the ABLE study, for example anaesthetists, A&E teams
Do you have any competing trials in which there is a possibility of coenrolment? We have many
coenrolment agreements in place now, but if there is a new study, please alert the trial office, which
will investigate whether or not coenrolment is possible
Is there any difficulty finding independent clinicians to sign the clinician agreement form? You need a
balance between the number of clinicians on the delegation log and those consultants not on the log
who can sign the clinician agreement form. Do you need to ‘fine tune’ or change this?
For the blood bank
Consider flagging potentially eligible patients in the blood bank on its IT system. Research staff can
alert the blood bank when they identify a potentially eligible patient and individuals could be flagged
electronically. If a request is during working hours, research staff could be contacted by the blood bank
if a flag is on the patient. If out of hours, the requesting clinical staff could be asked to consider
whether or not transfusion can be delayed until morning, reducing night-time non-urgent transfusions
and potentially enabling enrolment the next morning
If flagging is not possible on blood bank systems, ask the blood bank to call the research team during
daytime hours, when non-urgent RBC requests are made for ICU patients
IT, information technology.
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Audit of blood transfusion in participating intensive care units
In order to understand how the patients recruited to the ABLE trial compared with all patients receiving
blood transfusion in UK ICUs, we undertook an audit of 489 sequential ICU admissions to 15 out of 20
ABLE trial sites. Each site audited at least 30 sequential admissions, and used blood bank data to ascertain
and record all RBC transfusions during the hospital stay, including the numbers of transfusions and
whether or not the transfusion occurred pre, during or post ICU care.
Transfusion data were unavailable for six patients. The audit showed that 222 out of 483 (46%) of all
patients admitted to the typical UK ICUs received a RBC transfusion during their hospitalisation.
Transfused patients received a mean of 6.8 RBC units during hospitalisation. Data showed that 110 out
of 483 (23%) patients received RBCs prior to ICU admission [49/483 (10%), exclusively pre ICU admission].
These patients were ineligible for the ABLE trial. A total of 135 out of 483 (28%) patients received
RBCs during ICU stay [66/483 (14%), exclusively during ICU stay]. The mean RBC use for transfused
patients during ICU care was 4.4 RBC units per patient. A total of 73 out of 483 (15%) patients received
RBCs during the post-ICU discharge period [26/483 (5%), exclusively during the post-ICU period]. Many
patients received RBCs at multiple time points during their hospitalisation.
These data, collected during the ABLE trial recruitment, indicated that many patients received RBCs but
were either not eligible for the ABLE trial or were not included.
TABLE 5 Summary of process of follow-up with response rates
Process
Participants contacted
for follow-up at
6 months 12 months
Total number of participants 359 359
Death prior to follow-up time point, n 132 138
Patient alive at this time point, n (%) 227 (63) 221 (62)
Site advised no follow-up was feasible, n 2 2
Lost to follow-up at this time point, n 5 6
Withdrawn from the trial at this time point, n 18 19
Participants sent postal questionnaire, n 202 194
Follow-up questionnaire returned after first postal questionnaire, survivors, n (%) 94 (41) 85 (39)
Follow-up questionnaire not returned after first postal questionnaire, survivors, n (%) 108 (48) 109 (49)
Reminder postal questionnaire sent N/A 107a
Follow-up questionnaire returned after second postal questionnaire, survivors, n (%) N/A 40 (18)
Follow-up questionnaire not returned after second postal questionnaire, survivors, n (%) N/A 67 (30)
Attempted completion via telephone: successful, survivors, n (%) 45 (20) 3 (1)
Attempted completion via telephone: unsuccessful, survivors, n (%) 63b (28) 66b (30)
Follow-up completed, survivors, n (%) 139 (61) 128 (58)
N/A, not applicable.
a In two cases, a postal reminder was not sent, as the participants were not known at their listed address; follow-up was
attempted by telephone.
b These patients received up to five telephone calls (mean 2.6 telephone calls per patient) before being classified as lost to
follow-up.
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Concurrently, we examined the screening logs for the ABLE trial and found that of 3754 patients who
received RBCs during their ICU care, only 1035 (28%) were eligible for the ABLE trial.
Together, these data clearly showed that, despite the pragmatic design of the trial, the ABLE trial
population was only around 25% of ICU admissions, and this accounted for a minority of patients
receiving RBCs during ICU care.
DOI: 10.3310/hta21620 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 62
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Walsh et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
27

Chapter 4 Results of process of care and the
clinical outcomes
The results of the international ABLE trial, which included the majority of the UK cohort of patients,have been published previously.31 We present here a summary of the UK cohort, with comparison with
effects observed in the main trial cohort. The UK cohort was underpowered for the primary and secondary
trial outcomes, as expected from the outset of the project, but comparison with the main trial is useful to
understand any possible differences between the UK cohort and the international trial population.
Patients
The international trial cohort was recruited between March 2009 and May 2014. The UK cohort was
recruited between January 2012 and October 2014. The UK patients recruited after the international trial
sample size was achieved (over a period of 6 months) were included in this summary of the UK cohort and
the health economic evaluation. There were 293 patients recruited to the UK trial who were included in the
main trial analysis, previously published.31 In total, 359 patients were recruited in the UK (90% of the revised
400 patient sample size; see Figure 6 for timelines). In total, 354 patients were included in the UK cohort
reported here for clinical outcomes (multiple imputation enabled the inclusion of 357 patients in the
economic evaluation). These included 58 patients recruited after achievement of the international sample
size. In four cases there were no primary outcome data, and in one case a patient withdrew consent.
In the international trial, 2510 patients underwent randomisation; 80 (3.2%) were withdrawn after
randomisation because primary outcome data could not be obtained, leaving 2430 patients (1211 in the
group allocated to receive fresh blood and 1219 in the group allocated to receive standard-aged blood) in
the intention-to-treat analysis.
Baseline data were available for 2412 of the 2430 patients with primary outcome data. Of these 2430 patients,
94 (3.9%) did not receive any RBC transfusions. The overall rate of loss to follow-up was 3.2% at 90 days.
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FIGURE 6 Recruitment accrual over time to the UK ABLE trial. The revised trial target of 400 patients was agreed
with the HTA programme when the end date for the international trial was predicted.
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For the UK, the Consolidated Standards of Reporting Trials (CONSORT) flow diagram describing the trial is
shown in Figure 7. In total, 5989 patients received a blood transfusion during the first 7 days of ICU stay.
However, of these, 2081 did not meet the other inclusion criteria. Of the 3908 patients who met all
inclusion criteria, 2270 were excluded in accordance with the protocol. By far the most common reason
for exclusion, in 2021 patients, was the patient having had a transfusion earlier during their hospital stay.
This included transfusions undertaken prior to ICU admission, for example to treat haemorrhage or
perioperative blood loss. Of the 1638 patients who were eligible for randomisation, a high proportion
(n = 1279, 78%) were excluded for a variety of practical reasons that meant that randomisation and
Total ICU admissions
(n = 43,525)a
Inclusion criteria not met
(n = 2081)
Other reasons why not randomised
(n = 1279)
• Insufficient time, n = 97
• Randomisation system N/A, n = 1
• Maximum number enrolled, n = 1
• Units needed urgently, n = 5
• Transfusion cancelled, n = 2
• Large volume of RBCs, n = 9
• Other, n = 1164
    • Transfused out of hours, n = 957
    • Transfused prior to screening, n = 13
    • Transfused in theatre, n = 27
    • Other, n = 167
Received transfusion within
first 7 days
(n = 5989)
Eligible patients
(n = 1638)
Randomised
(n = 359)
Excluded patients
(n = 2270)
• Aged < 16 years, n = 6
• Terminal illness, n = 13
• Life-support measures withdrawn, n = 60
• Brain death, n = 3
• Already received a RBC transfusion, n = 2021
• Cardiac surgery, n = 20
• Required > 1 unit, n = 5
• Patient objection to transfusions, n = 4
• Autologous donation, n = 1
• Enrolled in competing trial, n = 26
• Clinician refusal, n = 9
• Consent denied, n = 21
• Proxy unavailable for consent, n = 4
• Previously enrolled in the ABLE trial, n = 4
• Report of RBC transfusion, n = 21
• Fresh RBCs unavailable, n = 5
• Rare blood type, n = 15
• More than one exclusion category, n = 28
• Unknown, n = 4
FIGURE 7 The CONSORT flow diagram for the UK ABLE trial. a, No admission data from three sites. N/A, not
applicable.
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group allocation were not feasible. The most common reason was transfusion at night (n = 957). In these
situations, delay of transfusion to enable randomisation was not considered clinically appropriate or safe,
but the randomisation procedure could not be organised either by clinical research staff or at the blood
bank level. In total, 359 patients were randomised in the UK cohort, out of 1638 (22%) eligible patients
according to the trial protocol. Five patients were not included in the primary analysis. In four cases, there
were no primary outcome data; in one case, a patient withdrew consent. Of these 354 patients, 179 were
randomised to the group allocated to receive fresh blood and 175 patients to the group allocated to
receive standard-aged blood.
Baseline characteristics of the patients for the ABLE trial UK cohort, and for the overall international trial,
are shown in Table 6. Patients had an age and sex profile typical of general ICU populations in the UK. The
illness severity, based on APACHE II score and requirement for organ support, was high and the majority
had significant levels of organ dysfunction based on the MODS score. Almost all patients were non-elective
TABLE 6 Baseline characteristics
Characteristic
Treatment group for
The UK ABLE cohort The international ABLE cohort
Fresh blood
(n= 179)
Standard-aged
blood (n= 175)
Total
(n= 354)
Fresh blood
(n= 1206)
Standard-aged
blood (n= 1206)
Total
(n= 2412)
Age (year) 60.8 ± 15.6 62.3± 17.0 61.6 ± 16.3 61.3 ± 16.7 61.0± 16.7 61.2 ± 16.7
Male sex 101 (56.4) 87 (49.7) 188 (53.1) 682 (56.6) 643 (53.3) 1325 (54.9)
Coexisting illness 67 (37.4) 71 (40.6) 138 (39.0) 512 (42.5) 514 (42.6) 1325 (54.5)
APACHE II score 22.5 ± 7.3 21.9± 6.7 22.2 ± 7.0 21.9 ± 7.7 21.6± 7.6 21.8 ± 7.6
Time from ICU
admission to
randomisation (days)
3.3 ± 2.0 3.3± 1.8 3.3 ± 1.9 2.4 ± 2.0 2.4± 2.1 2.4 ± 2.1
Time from
hospitalisation to ICU
admission (days)
3.2 ± 6.4 3.3± 6.9 3.2 ± 6.6 2.6 ± 6.6 2.7± 6.5 2.6 ± 6.5
Organ injury and support
MODS score 5.5 ± 3.1 5.4± 3.0 5.5 ± 3.1 5.0 ± 3.1 4.7± 3.1 4.9 ± 3.1
Invasive MV 175 (97.8) 164 (93.7) 339 (95.8) 1176 (97.5) 1174 (97.3) 2350 (97.4)
Renal replacement
therapy
40 (22.4) 48 (27.4) 88 (24.9) 324 (26.9) 354 (29.4) 678 (28.1)
Vasoactive support 109 (60.9) 112 (64.0) 221 (62.4) 750 (62.2) 765 (63.4) 1515 (62.8)
Type of admission
Emergency 166 (92.7) 161 (92.0) 327 (92.4) 1164 (96.5) 1169 (96.9) 2333 (96.7)
Elective 13 (7.3) 14 (8.0) 27 (7.6) 42 (3.5) 37 (3.1) 79 (3.3)
Major admission category
Medical 108 (60.3) 112 (64.0) 220 (62.1) 845 (70.1) 867 (71.9) 1712 (71.0)
Surgical 50 (27.9) 41 (23.4) 91 (25.7) 175 (14.5) 152 (12.6) 327 (13.6)
Trauma
Brain injury 15 (8.4) 16 (9.1) 31 (8.8) 110 (9.1) 106 (8.8) 216 (9.0)
No brain injury 6 (3.4) 6 (3.4) 12 (3.4) 76 (6.3) 80 (6.6) 156 (6.5)
Source: Lacroix et al.31
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ICU admissions. The majority had a medical diagnosis, most likely to be consistent with the non-eligibility
of patients receiving blood transfusion prior to ICU admission, which will include many surgical and trauma
patients. The UK ABLE trial cohort was similar to the international cohort, although there were more
elective ICU admissions in the UK ABLE trial cohort.
Intervention
Table 7 shows the comparison of transfusion practice between the groups, between the UK ABLE trial and
the international trial. In the international trial, a total of 5198 RBC units were given to patients in the group
allocated to receive fresh blood and 5210 to patients in the group allocated to receive standard-aged blood.
The pre-transfusion haemoglobin concentration was similar in the international cohort to the UK ABLE trial
and the values indicated a restrictive transfusion practice consistent with current evidence. Patients received
a similar number of RBC units in both groups. This was the case for the overall trial, and for the UK cohort.
There was excellent separation of storage-age profile, which was similar in the UK to the international
cohort. The difference between the distribution of storage age in each group was clinically relevant (see
Figure 8; reproduced from full trial data). Protocol compliance was high. The rate of adherence to the
transfusion protocol was 95.4% for all red blood cells transfused, with 100% of patients allocated to
TABLE 7 Anaemia and RBC transfusions
Variable
Treatment group for
The ABLE UK cohort The international ABLE trial
Fresh blood
Standard-aged
blood p-value Fresh blood
Standard-aged
blood p-value
Haemoglobin concentration in the ICU
Number of patients evaluated 179 175 – 1207 1206 –
Concentration (g/dl) before
first transfusiona
7.67 ± 0.86 7.77 ± 0.83 0.26 7.69 ± 1.28 7.64 ± 1.09 0.27
Lowest concentration (g/dl)
after randomisationa
7.43 ± 0.72 7.56 ± 0.69 0.08 7.34 ± 1.46 7.31 ± 1.41 0.61
RBC transfusions after randomisation
Patients who received at least
one transfusion, n/N (%)
175/179
(97.8)
173/175
(98.9)
0.68 1163/1207
(96.4)
1173/1208
(97.1)
0.31
Time from randomisation to
first transfusion (hours)
8.55 ± 35.1 5.74 ± 22.4 0.37 10.3 ± 16.2 9.7 ± 16.2 0.43
Number of RBC units per
patient who received at least
one transfusion
4.0 ± 4.8 3.6 ± 3.7 0.40 4.3 ± 5.2 4.3 ± 5.5 0.98
Duration of storage of all RBC
units (days)
5.2 ± 2.8 20.7 ± 7.3 < 0.001 6.1 ± 4.9 22.0 ± 8.4 < 0.001
Adherence to transfusion protocol, n/N (%)
Patients 152/175
(86.9)
154/173
(89.0)b
– 977/1163
(84.0)
1206/1206
(100)
–
RBC units 680/721
(94.3)
605/637
(95.0)b
– 4723/5198
(90.9)
5210/5219
(100)
–
a All values are mean (± SD).
b This figure would be 100% if adherence was defined as meaning the oldest available RBC unit. In some cases this was
< 8 days, which in these figures has been counted as ‘non-protocol’, but was the standard issue from the blood bank on
that occasion.
Source: Lacroix et al.31
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FIGURE 8 Distribution of RBC units in accordance with length of storage, as transfused to patients allocated to the fresh blood arm (green bars) and to the standard arm
(black bars). Source: Lacroix et al.31
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receive standard-aged blood receiving only standard-issue RBCs and 84.0% of patients allocated to receive
fresh blood receiving only red blood cells stored for ≤ 7 days. In the group allocated to receive fresh blood,
only 6.6% of the patients received > 1 RBC unit that had been stored for > 7 days, and only 4.6% received
> 2 units that had been stored for > 7 days. Most patients in the group allocated to receive fresh blood [238
of 249 patients (95.6%)] who received only one RBC transfusion received exclusively RBC units that had
been stored for < 8 days.
Primary outcome
In the international trial, at 90 days after randomisation, 37.0% of patients in the group allocated to
receive fresh blood and 35.3% of patients in the group allocated to receive standard-aged blood had died.
The unadjusted and adjusted risk differences are shown in Table 8. There was no evidence of any clinically
or statistically important difference between the groups. The proportion of patients who died was similar
in the UK ABLE trial cohort.
Secondary analyses
In the international trial, the survival analysis of the time to death showed a hazard ratio in the group
allocated to receive fresh blood, compared with the group allocated to receive standard-aged blood, of 1.1
(95% CI 0.9 to 1.2; p = 0.38). No significant difference in mortality was observed between the groups on
the basis of follow-up duration, age, number of units transfused, APACHE II score or admission category.
Differences between the groups in the UK ABLE trial cohort were similar to those in the international
cohort (see Table 8).
In the international trial, no significant differences were observed with respect to major illnesses, duration
of respiratory, haemodynamic or renal support, or length of stay in the ICU or hospital. There were also
no differences in reported transfusion reactions. Data were comparable for the UK ABLE trial subgroup
(see Table 8).
Data for other secondary outcomes are shown in Table 9. There were no differences between the groups
in the international trial, and data were similar for the UK ABLE trial cohort.
The per-protocol analysis of the primary outcome, which included only patients who received a transfusion,
showed no difference between the groups in the international trial, and data were comparable for the
UK ABLE trial cohort. In the sensitivity analysis of the primary outcome, in which outcomes of the patients in
the fresh-blood group who received only RBCs that had been stored for ≤ 7 days, were compared with the
outcomes in patients in the standard-aged blood group, who received RBCs that had been stored for
> 7 days, also showed no differences between the groups. Data are shown in Tables 10 and 11.
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TABLE 8 Primary outcome and secondary outcomes related to death and major illness
Outcome
Treatment group for the ABLE-UK cohort Treatment group for the international ABLE trial cohort
Fresh blood
Standard-aged
blood
Crude absolute
risk difference
(95% CI)
Adjusted absolute
risk difference
(95% CI)
Fresh
blood
Standard-aged
blood
Crude absolute
risk difference
(95% CI)
Adjusted absolute
risk difference
(95% CI)
Patients, n/N (%) Patients, n/N (%) Percentage points Percentage points % % Percentage points Percentage points
Primary outcome: death
by day 90
58/179 (32.4) 61/175 (34.9) –2.5 (–12.3 to 7.4) –1.3 (–8.7 to 6.1) 37.0 35.3 1.7 (–2.1 to 5.5) 1.7 (–1.6 to 4.9)
Secondary outcomes
Death in ICU 42/179 (23.5) 47/175 (26.9) –3.4 (–12.4 to 5.6) – 27.0 24.2 2.5 (–1.0 to 5.9) –
Death in hospital 52/178 (29.2) 59/175 (33.7) –4.5 (–14.2 to 5.2) – 33.3 31.9 1.9 (–2.3 to 5.1) –
Death by day 28 48/179 (26.8) 53/175 (30.3) –3.5 (–12.9 to 5.9) – 30.6 28.8 1.7 (–1.9 to 5.4) –
Major illness
MODS score 24/179 (13.4) 30/175 (17.1) –3.7 (–11.2 to 3.8) – 13.4 13.0 0.4 (–2.3 to 3.1) –
Acute respiratory
distress syndrome
10/179 (5.6) 10/175 (5.7) –0.1 (–4.9 to 4.7) – 5.7 6.6 –0.9 (–2.8 to 1.0) –
Cardiovascular failure 6/179 (3.35) 7/175 (4.0) –0.65 (–4.6 to 3.3) – 5.1 4.2 0.8 (–0.8 to 2.5) –
Cardiac ischaemia or
infarction
6/179 (3.35) 6/175 (3.43) –0.08 (–3.9 to 3.7) – 4.5 3.7 0.8 (–0.7 to 2.4) –
Deep-vein thrombosis
or pulmonary
embolism
0/179 (0) 2/175 (1.14) –1.1 (–2.7 to 0.4) – 3.6 3.6 0.0 (–1.5 to 1.5) –
Nosocomial infection 64/179 (35.75) 52/175 (29.71) 6.04 (–3.7 to 15.8) – 34.1 31.3 2.8 (–0.9 to 6.5) –
Acute transfusion
reaction
2/179 (1.12) 1/175 (0.57) 0.55 (–1.4 to 2.5) – 0.3 0.5 –0.2 (–0.7 to 0.3) –
Source: Lacroix et al.31
D
O
I:10.3310/hta21620
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2017
VO
L.21
N
O
.62
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2017.
This
w
ork
w
as
produced
by
W
alsh
et
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professionaljournals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
35
TABLE 9 Other secondary outcomes
Outcome
Treatment group for the ABLE UK cohort
Treatment group for the international ABLE
trial cohort
Fresh blood
Standard-aged
blood
Mean difference
(95% CI)
Fresh blood
Standard-aged
blood
Mean difference
(95% CI)Mean ± SD Mean ± SD Mean ± SD Mean ± SD
MODS score
Highest score 7.1 ± 3.4 6.9± 3.1 0.2 (–0.5 to 0.9) 6.4± 3.2 6.2 ± 3.2 0.2 (–0.1 to 0.4)
Delta score 1.6 ± 2.0 1.4± 1.8 0.1 (–0.3 to 0.5) 1.4 ± 1.8 1.4 ± 1.9 –0.1 (–0.2 to 0.1)
Duration of supportive care (days)
MV 13.8 ± 11.4 14.1± 11.2 –0.3 (–2.6 to 2.1) 15.0± 18.0 14.7 ± 14.9 0.3 (–1.1 to 1.6)
Cardiac or
vasoactive drugs
6.9 ± 7.6 6.6± 8.3 0.3 (–1.4 to 1.9) 7.1± 10.2 7.5 ± 11.2 –0.4 (–1.2 to 0.5)
Renal
replacement
therapy
4.4 ± 10.1 4.3± 9.8 0.1 (–2.0 to 2.1) 2.5± 10.1 2.3 ± 8.3 0.2 (–0.6 to 0.9)
Length of stay (days)
In ICU 13.8 ± 9.6 14.3± 10.5 –0.5 (–2.6 to 1.6) 15.3± 15.4 15.3 ± 14.8 0.1 (–1.2 to 1.3)
In hospital 32.7 ± 28.0 32.0± 31.5 0.7 (–5.5 to 7.0) 34.4± 39.5 33.9 ± 38.8 0.5 (–2.6 to 3.7)
Source: Lacroix et al.31
TABLE 10 Per-protocol analysis (at least one transfusion). This analysis included only patients who actually received
a red blood cell transfusion
Outcome
Treatment group for the ABLE UK cohort
Treatment group for the international
ABLE trial cohort
Fresh blood
Standard-aged
blood
Crude absolute
risk difference
(95% CI)
Fresh
blood
Standard-aged
blood
Crude absolute
risk difference
(95% CI)
Patients,
n/N (%)
Patients,
n/N (%)
Percentage
points % %
Percentage
points
Primary outcome:
death by day 90
57/175
(32.6)
60/173 (34.7) –2.1 (–12.0 to 7.8) 36.7 34.2 2.5 (–1.4 to 6.4)
Source: Lacroix et al.31
TABLE 11 Per-protocol analysis (full compliance). This analysis included only patients in whom there was full
compliance with the storage age allocation of the fresh and standard-aged red blood cell groups
Outcome
Treatment group for the ABLE UK cohort
Treatment group for the international
ABLE trial cohort
Fresh blood
Standard-aged
blood
Crude absolute
risk difference
(95% CI)
Fresh
blood
Standard-aged
blood
Crude absolute
risk difference
(95% CI)
Patients,
n/N (%)
Patients,
n/N (%)
Percentage
points % %
Percentage
points
Primary outcome:
death by day 90
50/152
(32.9)
54/154 (35.1) –2.2 (–12.8 to 8.4) 36.9 34.1 2.8 (–1.4 to 6.9)
Source: Lacroix et al.31
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Chapter 5 Cost–utility analysis of fresh blood
versus standard-aged blood in the Age of BLood
Evaluation study
Aim
In this study we investigated the cost-effectiveness of fresh blood versus standard-aged blood in critical
care patients. The sample comprised patients in the UK ABLE trial.
Methods
Overview of economic evaluation
We undertook a cost–utility analysis to compare the costs and outcomes of fresh blood versus standard-aged
blood for the 359 patients in the UK arm of the ABLE trial. Two patients had no study measurements and so
were not included in the analysis, giving a sample size of 357 for the cost–utility analysis. This is a slightly
larger number than the sample size for the main UK analysis described in the previous chapter, made
possible by the use of multiple imputation in the economic analysis to deal with missing data. Fresh blood
was defined as blood donated within the past 6.1 (± SD 4.9) days and standard-aged blood within 22.0
(± SD 8.4) days. The outcome measure was QALYs, which combine length of life and quality of life, based on
the National Institute for Health and Care Excellence (NICE)’s recommendations.32 Cost-effectiveness was
expressed as incremental net monetary benefits (INMBs).32 The analysis took a UK NHS and personal social
services perspective.32 Costs were calculated in 2015 UK pounds and inflated where necessary.33 The time
horizon was 1 year, reflecting the follow-up period in the trial. Extrapolation beyond the end of the trial was
not undertaken because the within-trial analysis found no evidence of significant differences in costs or
benefits between groups; 1 year was long enough to reflect all important differences in costs or outcomes
between treatments with fresh blood and standard-aged blood. Given the time horizon, discounting was not
applied to costs or outcomes.
Resource use and costs
For every patient we calculated the cost of the index hospitalisation (from hospital admission to hospital
discharge) and of follow-up to 12 months post randomisation based on resource use data collected in the
trial. We included the costs of blood transfusions, fresh-frozen plasma and platelets, length of stay in
hospital regular inpatient wards and in the ICU, use of MV, vasopressors, inotropes, continuous renal
replacement therapy (CRRT), haemodialysis and peritoneal dialysis in the ICU. Post-discharge costs
included GP visits in the clinic and at home, and telephone consultations; district and practice nurse visits;
physiotherapist, occupational therapist and speech and language therapist visits; dietitian, home care
worker (e.g. Meals on Wheels), social worker, psychological therapist, counsellor and aids and adaptation
worker visits; specialist nurse visits (substance misuse nurses, Macmillan Cancer Support nurses); day
hospital visits; A&E visits; outpatient appointments; and readmissions to hospital, including surgical
procedures and ICU spells. The questionnaire used to collect the data is included in Appendix 5.
Unit costs were obtained from published sources and inflated where appropriate.33–38 The unit costs per unit
of fresh blood and standard-aged blood were assumed to be the same, as there is no differential pricing
by age of blood, but the sensitivity of the findings to this assumption was investigated in the sensitivity
analysis. We included blood transfusion laboratory issue costs.34 Administration costs were assumed to be
included in the ICU and inpatient costs per stay, although in any case, since there were no between-group
differences in the number of blood products received, these costs would be the same in both groups and
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would not affect the incremental costs. Consultant, district, practice and specialist nurse, and specialist
therapist visits were assumed to last 1 hour; GP clinic visits were assumed to last 11.7 minutes. Unit costs of
hospital inpatient and ICU stays were daily costs applied to length of stay data collected in the trial.
Utilities and quality-adjusted life-years
Generic health status was described at 6 and 12 months post randomisation, using the EQ-5D descriptive
system.29,39 More frequent measurement was not considered to be feasible, given the challenges of
complete follow-up in this group. The EQ-5D contains five dimensions: mobility, self-care, usual activities,
pain and discomfort, anxiety and depression). The UK study centres were randomised to using either the
EQ-5D-3L or the EQ-5D-5L at both follow-up time points (to enable the methodological substudy described
in Chapter 6). Fifty per cent of centres were randomised to each version and the same version was used at
both follow-up points. For each dimension, there are three levels in the EQ-5D-3L (no problems, some
problems and unable to/extreme problems) and five levels in the EQ-5D-5L version (no problems, slight
problems, moderate problems, severe problems and unable to/extreme problems). As patients recruited to
the trial were initially critically ill, completion of the EQ-5D at randomisation was not possible. Therefore,
baseline utility was assumed to be zero for all patients. This assumption has been made in previous studies
in which baseline utility measurement was not possible.40 EQ-5D health states were converted into utility
values using formulae that attach weights to each level in each dimension based on valuations by general
population samples. Different formulae and value sets were used to calculate utility values for the EQ-5D-3L
and EQ-5D-5L, although both value sets were based on the UK general population.30,41 Utility values of one
represent full health, values of zero are equivalent to death and negative values represent states worse than
death. Patients who died were assigned a utility value of zero at all subsequent time periods. A utility profile
was constructed for every patient, assuming a straight-line relation between their utility values at each
measurement point. QALYs for every patient from baseline to 12 months were calculated as the area under
the utility profile. The implications of our assumptions were as follows: for patients who survived up to
6 months, QALYs up to 6 months were calculated using the EQ-5D scores at 6 months, assuming a EQ-5D
score of zero units at baseline, and a linear interpolation between baseline and 6 months; for patients who
died between baseline and 6 months, we assumed that they accrued zero QALYs; for patients who survived
up to 12 months, we used a linear interpolation between EQ-5D scores at 6 and 12 months; and for
patients who died between 6 and 12 months, and for whom a EQ-5D score at 6 months was available, a
linear interpolation was applied between the 6-month EQ-5D score and the date of death, at which point a
zero EQ-5D score was applied thereafter. We assigned all the EQ-5D data that were collected to either the
6- or 12-month measurement points, irrespective of the precise time when these were actually measured.
Dealing with missing data
The extent of missing data across all of the individual variables in the analysis ranged from 0% to 25.6%.
Multiple imputation was used to impute missing data for index hospitalisation costs, costs of follow-up
up to 12 months, and utility values at 6 and 12 months. Age, sex, study centre, treatment allocation,
comorbidities at hospital admission [separate indicators for pre-existing significant comorbid illnesses
comprising severe lung disease with symptoms at rest, previous myocardial infarction, severe heart disease
with symptoms at rest, disabling stroke, chronic renal failure (dialysis dependent), type 1 or type 2 diabetes
mellitus with evidence of end-organ damage, metastatic cancer, immunosuppressive therapy, chronic
institutionalisation for > 6 months, deep-vein thrombosis], APACHE II score on ICU admission and MODS
score on ICU admission were included in the imputation as additional explanatory variables. We used
an iterative Markov chain Monte Carlo procedure based on multivariate normal regression, generating
20 imputed data sets.
Statistical methods
Mean costs, outcomes and net monetary benefits (NMBs) were compared between UK patients randomly
assigned to receive fresh blood or standard-aged blood, irrespective of which treatment was administered.
We calculated differences in mean costs, QALYs and INMBs between groups. NMBs for patients allocated
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to receive fresh (F) and standard-aged blood (S) were calculated as the mean QALYs per patient (Q)
multiplied by the maximum willingness to pay for a QALY (R) minus the mean cost per patient (C):
NMBi = Qi × R –Ci for i = F, S. (1)
The NMBs are likely to be negative, reflecting a relatively high cost incurred by each treatment group
in the first 12 months compared with the likelihood of limited QALYs being accrued in each group over
the same period. The treatment option with the highest INMB (either most positive or least negative) is
preferred on cost-effectiveness grounds. The INMB was calculated as the difference in mean QALYs per
patient with fresh blood versus standard-aged blood multiplied by the maximum willingness to pay for a
QALY minus the difference in mean cost per patient:
INMB = (QF –QS) × R – (CF –CS). (2)
We used the cost-effectiveness threshold range recommended by NICE (£20,000 to £30,000)32 as the
lower and upper limits of the maximum willingness to pay for a QALY (R). If the INMB is positive (negative)
then fresh blood (standard-aged blood) was preferred on cost-effectiveness grounds. QALYs gained and
incremental costs were adjusted for age, sex, study centre, comorbidities, APACHE II score and MODS
score using regression analysis. For each of the 20 imputed data sets, we ran 1000 bootstrap replications
using non-parametric bootstrapping, resampling observations with replacement. Results were combined
using equations described by Briggs et al.42 to calculate standard errors around mean values accounting for
uncertainty in imputed values, skewness of cost and utility data and sampling variation. Standard errors
were used to calculate 95% CIs around point estimates.
Sensitivity analyses
A cost-effectiveness acceptability curve43 showing the probability that fresh blood was cost-effective compared
with standard-aged blood at a range of values for the maximum willingness to pay for a QALY was generated
based on the proportion of the bootstrap replications across all 20 imputed data sets with positive INMBs.44
The probability that fresh blood was cost-effective at a maximum willingness to pay for a QALY of £20,000 and
£30,000 was based on the proportion of bootstrap replications with positive INMBs at these values. This shows
the probability that fresh blood would be cost-effective compared with standard-aged blood based on the
estimated costs and outcomes in the two treatment groups and the uncertainty in these estimates. Note the
probability that standard-aged blood is cost-effective is one minus this probability figure. We undertook further
univariate sensitivity analyses: (1) increasing the cost of fresh blood by 25%; (2) increasing the cost of standard-
aged blood by 25%; (3) changing the daily cost of non-invasive and invasive MV by ± 25%; (4) changing the
daily cost of vasopressors and inotropes by ± 25%; (5) changing the daily cost of CRRT, haemodialysis and
peritoneal dialysis by ± 25%; (6) changing the daily cost of ICU admission by ± 25%; and (7) changing the daily
cost of an inpatient stay by ± 25%.
Results
In our sample, the mean number of units of RBCs transfused was 4.1 RBC units [standard deviation (SD)
4.9 RBC units] in the group allocated to receive fresh blood (n = 181) and 3.7 RBC units (SD 3.7 RBC units)
in the group allocated to receive standard-aged blood (n = 176; Table 12). The mean number of units of
fresh-frozen plasma transfused was 1.1 RBC units (SD 5.1 RBC units) in the group allocated to receive
fresh blood (n = 181) and 0.6 RBC units (SD 2.1 RBC units) in the group allocated to receive standard-aged
blood (n = 176). The mean number of units of platelets transfused was 0.6 RBC units (SD 2.3 RBC units) in
the group allocated to receive fresh blood (n = 181) and 0.3 RBC units (SD 1.1 RBC units) in the group
allocated to receive standard-aged blood (n = 176).
The mean length of stay in hospital was 36.9 days (SD 28.8 days) in the group allocated to receive fresh
blood and 36.3 days (SD 33.2 days) in the group allocated to receive standard-aged blood. Mean length of
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TABLE 12 Resource use, unit costs, utility values and QALYs per patient (complete cases)
Item of resource use
Trial group
Unit
cost (£)
Missing
(%)Fresh blood
Standard-aged
blood
Blood units (all patients),a mean (SD)
Number of units of RBCs 4.1 (4.9), 181 3.7 (3.7), 176 121.85 0.6
Number of units of fresh-frozen plasma 1.1 (5.1), 181 0.6 (2.1), 176 28.46 0.6
Number of units of platelets 0.6 (2.3), 181 0.3 (1.1), 176 303.51 0.6
Inpatient and ICU costs (all patients), mean (SD)
Number of days on non-invasive MV before invasive MV 0.4 (2.6), 181 0.5 (2.5), 176 874.88 0.6
Number of days on invasive MV 12.3 (9.4), 181 12.5 (10.8), 176 874.88 0.6
Number of days on non-invasive MV after invasive MV 1.1 (6.9), 181 1.0 (3.7), 176 874.88 0.6
Number of days on vasopressors 5.5 (6.8), 181 5.1 (6.4), 176 113.35 0.6
Number of days on inotropes 1.3 (3.5), 181 1.5 (3.9), 176 113.35 0.6
Number of days on CRRT 3.2 (6.4), 181 3.2 (6.2), 176 152.49 0.6
Number of days on haemodialysis 0.9 (7.2), 181 1.1 (6.2), 176 152.49 0.6
Number of days on peritoneal dialysis 0.1 (2.0), 181 0.01 (0.2), 176 152.49 0.6
Number of days in ICU 14.8 (9.5), 179 15.3 (10.5), 175 640.65 1.4
Number of days in hospital 36.9 (28.8), 178 36.3 (33.2), 174 214.00b 1.9
Primary/community care costs post discharge (survivors only), mean (SD)
Number of GP visits in clinic 6.3 (6.8), 76 3.9 (4.2), 83 65.00 –
Number of GP visits at home 1.0 (1.8), 76 1.8 (4.5), 83 114.00
Number of GP telephone consultations 1.7 (2.2), 76 1.6 (2.3), 83 27.00
Number of district nurse visits (community nurse) 11.6 (32.5), 76 12.5 (29.6), 83 67.00
Number of practice nurse visits 2.8 (5.3), 76 3.4 (8.8), 83 56.00
Number of NHS physiotherapist visits (hospital) 3.0 (5.8), 76 2.9 (6.7), 83 38.00
Number of occupational therapist (community) visits 1.4 (5.5), 76 1.7 (4.9), 83 44.00
Number of speech and language therapist (hospital) visits 0.9 (4.9), 76 0.7 (4.6), 83 38.00
Number of dietitian visits 1.3 (2.5), 76 0.6 (1.7), 83 38.00
Number of home care worker visits 13.5 (57.1), 76 19.4 (107.9), 83 24.00
Number of social worker visits 0.4 (1.4), 76 0.4 (1.2), 83 57.00
Number of psychological therapist (psychologist,
psychiatrist, psychology counsellor) visits
1.2 (5.3), 76 0.6 (2.0), 83 139.00
Number of counsellor visits 0.7 (3.2), 76 0.1 (0.7), 83 44.00
Number of day hospital visits 1.6 (4.8), 76 1.9 (12.2), 83 113.00
Number of aids and adaptations worker visits 0.5 (1.2), 76 0.7 (1.7), 83 57.00
Number of substance misuse nurse visits 0.03 (0.3), 76 0.1 (0.5), 83 56.00
Number of Macmillan Cancer Support nurse visits 0.2 (1.1), 76 0.0 (0.0), 83 25.00
Number of other types of visit 1.0 (4.4), 76 11.0 (80.2), 83 Various
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stay in the ICU was 14.8 days (SD 9.5 days) in the group allocated to receive fresh blood (n = 179) and
15.3 days (SD 10.5 days) in the group allocated to receive standard-aged blood (n = 175). While in the
ICU, the mean length of use of invasive MV was 12.3 days (SD 9.4 days) in the group allocated to receive
fresh blood (n = 181) and 12.5 days (SD 10.8 days) in the group allocated to receive standard-aged blood
(n = 176). The mean number of days on vasopressors and inotropes was 5.5 days (SD 6.8 days) and 1.3
days (SD 3.5 days), respectively, in the group allocated to receive fresh blood and 5.1 days (SD 6.4 days)
and 1.5 days (SD 3.9 days), respectively, in the group allocated to receive standard-aged blood. Mean
number of days of CRRT was 3.2 days (SD 6.4 days) in the group allocated to receive fresh-blood (n = 181)
and 3.2 days (SD 6.4 days) in the group allocated to receive standard-aged blood (n = 176).
Post discharge, surviving patients in both groups used primary care and community care services. The
mean number of GP visits in the clinic up to 12 months was 6.3 visits (SD 6.8 visits) in the group allocated
to receive fresh blood (n = 76) and 3.9 visits (SD 4.2 visits) in the group allocated to receive standard-aged
blood (n = 83). GP visits at home or GP telephone consultations were less frequent. The mean number of
district nurse visits was 11.6 visits (SD 32.5 visits) in the group allocated to receive fresh blood group and
12.5 visits (SD 29.6 visits) in the group allocated to receive standard-aged blood. The mean number of
home care worker visits was 13.5 visits (SD 57.1 visits) in the group allocated to receive fresh blood and
19.4 visits (SD 107.9 visits) in the group allocated to receive standard-aged blood. Less frequent in both
groups were visits to a practice or specialist nurse, physiotherapist, psychologist, occupational therapist,
speech and language therapist, dietitian, counsellor or social worker. Post discharge, patients in both
groups used secondary care services. The mean number of A&E visits was 0.7 visits (SD 1.3 visits) in the
TABLE 12 Resource use, unit costs, utility values and QALYs per patient (complete cases) (continued )
Item of resource use
Trial group
Unit
cost (£)
Missing
(%)Fresh blood
Standard-aged
blood
Secondary care costs post discharge (survivors only)
Number of A&E visits, mean (SD) 0.7 (1.3), 76 0.9 (2.8), 83 140.59 –
Number of outpatient clinic visits, mean (SD) 4.6 (4.6), 76 6.0 (8.2), 83 113.00
Number (%) of patients readmitted to hospitalc
0 times 44 (58), 76 55 (66), 83 – –
1 time 16 (21), 76 13 (16), 83 –
2 times 8 (11), 76 4 (5), 83 –
3 times 6 (8), 76 5 (6), 83 –
4 times 2 (3), 76 2 (2), 83 –
5 times 0 (0), 76 4 (5), 83 –
Number of days in hospital if readmitted, mean (SD) 8.0 (15.5), 60d 7.9 (16.4), 66c 530–641e
a A blood transfusion laboratory issue cost of £2 per unit was also included.34
b This unit cost is applied to days on the regular inpatient ward only (not to days in the ICU).
c The figures for each group are number (%) of patients rather than mean (SD).
d The number of observations is the number of readmissions, not the number of patients.
e Different unit costs are applied to ICU stays and stays on a regular inpatient ward.
Notes
Costs are in 2015 UK pounds.
All data are raw data with no imputed values.
The ‘missing (%)’ column shows the number of missing data for each variable included in the analysis across all 359 patients
(182 were assigned to receive fresh blood and 177 were assigned to receive standard-aged blood).
Figures are not reported for post-discharge resource use, as this relates to survivors only.
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group allocated to receive fresh blood group and 0.9 visits (SD 2.8 visits) in the group allocated to receive
standard-aged blood. The mean number of outpatient clinic visits was 4.6 visits (SD 4.6 visits) in the group
allocated to receive fresh blood and 6.0 visits (SD 8.2 visits) in the group allocated to receive standard-aged
blood. In the group allocated to receive fresh blood, 42% of patients were readmitted to hospital at least
once for a mean period of 8.0 days; in the group allocated to receive standard-aged blood, these figures
were 34% and 7.9 days.
Accounting for missing data, the mean total cost per patient was £32,346 (95% CI £29,306 to £35,385)
in patients receiving fresh blood (n = 181) and £33,353 (95% CI £29,729 to £36,978) in patients receiving
standard-aged blood (n = 176; Table 13). In both groups, approximately 85% of the total costs were
incurred during the index hospital admission and 15% during follow-up.
Mean utility values were similar for the two groups and over time (see Table 13). Mean total QALYs per
patient were 0.207 (95% CI 0.158 to 0.256) in the group allocated to receive fresh blood and 0.213 in
the group allocated to receive standard-aged blood (95% CI 0.170 to 0.257).
As expected, at a maximum willingness to pay for a QALY of £20,000, the NMBs for the group allocated to
receive fresh blood and the group allocated to receive standard-aged blood were negative: –£28,201
(95% CI –£31,323 to –£25,119) and –£29,102 (95% CI –£32,596 to –£25,609), respectively (see Table 13).
Furthermore, at a maximum willingness to pay for a QALY of £30,000, the NMBs for the group allocated
to receive fresh blood and the group allocated to receive standard-aged blood were negative: –£26,128
(95% CI –£29,345 to –£22,911) and –£26,978 (95% CI –£30,489 to –£23,465), respectively (see Table 13).
Mean costs and QALYs and NMBs were similar for complete cases (Table 14), with 30–50% missing data
on total costs and QALYs.
TABLE 13 Mean utility values, QALYs and costs per patient (multiple imputation)
Variable
Trial group, mean (95% CI)
Fresh blood Standard-aged blood
Cost (£) of index admission 28,158 (25,646 to 30,669) 28,666 (25,589 to 31,743)
Cost (£) of follow-up 4188 (2599 to 5778) 4687 (2961 to 6413)
Total cost (£) 32,346 (29,306 to 35,385) 33,353 (29,729 to 36,978)
Utility values
Baseline 0 (0 to 0) 0 (0 to 0)
6 months 0.273 (0.205 to 0.340) 0.284 (0.222 to 0.345)
12 months 0.284 (0.217 to 0.351) 0.283 (0.221 to 0.346)
QALYs 0.207 (0.158 to 0.256) 0.213 (0.170 to 0.257)
NMB (£)
20,000 –28,201 (–31,283 to –25,119) –29,102 (–32,596 to –25,609)
30,000 –26,128 (–29,345 to –22,911) –26,978 (–30,489 to –23,465)
Notes
Costs are in 2015 UK pounds.
Data include values imputed using multiple imputation (see Dealing with missing data).
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There were no significant differences in costs between the two groups (mean incremental cost for the group
allocated to receive fresh blood vs. the group allocated to receive standard-aged blood: –£231, 95% CI
–£4876 to £4415) or in outcomes (mean QALYs gained –0.010, 95% CI –0.078 to 0.057) (Table 15).
The INMBs for the group allocated to receive fresh blood versus the group allocated to receive standard-
aged blood were not significantly different from zero at a maximum willingness to pay for a QALY of
£20,000 (mean £25, 95% CI –£4587 to £4637) and £30,000 (mean –£77, 95% CI –£4821 to £4666).
TABLE 14 Mean utility values, QALYs and costs per patient (complete cases)
Variable
Trial group
Fresh blood Standard-aged blood
Mean (95% CI)
Missing,
n (%) Mean (95% CI)
Missing,
n (%)
Cost (£) of index
admission
26,178 (23,244 to 29,111) 178 (1.7) 24,468 (21,471 to 27,466) 174 (3.9)
Cost (£) of follow-up 3857 (2093 to 5621) 102 (43.7) 4395 (2543 to 6246) 116 (35.9)
Total cost (£) 30,034 (26,377 to 33,692) 102 (43.7) 28,863 (25,312 to 32,414) 116 (35.9)
Utility values
Baseline 0 (0 to 0) 181 (0) 0 (0 to 0) 176 (2.8)
6 months 0.27 (0.19 to 0.34) 122 (32.6) 0.26 (0.20 to 0.33) 131 (27.6)
12 months 0.28 (0.21 to 0.36) 126 (30.4) 0.26 (0.20 to 0.33) 132 (27.6)
QALYs 0.20 (0.15 to 0.26) 111 (38.7) 0.20 (0.15 to 0.25) 117 (35.4)
NMB (£)
20,000 –25,972 (–29,630 to –22,313) 98 (45.9) –24,898 (–28,238 to –21,557) 108 (38.6)
30,000 –23,940 (–27,717 to –20,163) 98 (45.9) –22,915 (–26,250 to –19,579) 108 (38.6)
Notes
Costs are in 2015 Great British pounds.
All data are raw data with no imputed values.
The ‘missing’ column shows the number of missing data for each variable included in the analysis across all 359 patients
(182 were assigned to receive fresh blood and 177 were assigned to receive standard-aged blood).
TABLE 15 Incremental cost-effectiveness of the group allocated to receive fresh vs. standard-aged blood
Variable
Incremental cost (£),
mean (95% CI)
QALYs gained, mean
(95% CI)
INMB (£), mean (95% CI)
20,000 30,000
Base casea –231 (–4876 to 4415) –0.010 (–0.078 to 0.057) 25 (–4587 to 4637) –77 (–4821 to 4666)
No adjustmentb –1007 (–5736 to 3722) –0.0053 (–0.071 to 0.061) 902 (–3769 to 5572) 849 (–3931 to 5628)
Complete-case
analysisc
1778 (–3480 to 7036) 0.013 (–0.065 to 0.090) –1526 (–6648 to 3596) –1399 (–6626 to 3827)
a Data include values imputed using multiple imputation (see Dealing with missing data). The QALYs gained, incremental
cost and INMB figures are for the group allocated to receive fresh blood minus those of the group allocated to receive
standard-aged blood and are adjusted for potential confounders (see Dealing with missing data).
b As for the base-case analysis, except that the QALYs gained and the incremental costs are unadjusted.
c As for the base-case analysis, except that there is no multiple imputation of missing values and the 95% CIs were
derived from 1000 bootstrap replications of a single data set containing 46 patients from the group allocated to receive
fresh blood and 50 from the group allocated to receive standard-aged blood with no missing values.
Note
Costs are in 2015 UK pounds.
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At a maximum willingness to pay for a QALY of £20,000 and £30,000, the probability that fresh blood is
cost-effective was 0.52 and 0.49, respectively (Figure 9); as noted, the probability that standard-aged
blood is cost-effective is one minus this figure, indicating that the costs and outcomes for the two
treatment groups were similar.
Incremental costs, QALYs gained and INMBs for the group allocated to receive fresh blood versus the
group allocated to receive standard-aged blood remained not significantly different from zero when
rerunning the analysis without adjusting for potential confounding factors, and using complete cases
(see Table 15).
The results were not sensitive to changes in the cost of fresh blood and standard-aged blood, nor to
changes of admission and follow-up costs; INMBs did not vary much from baseline values and in every
case the INMB was not significantly different from zero (Table 16).
Summary
Our economic analysis to evaluate the cost-effectiveness of using fresh blood units versus standard-aged
blood units for transfusions in critically ill patients in the UK showed that there are no differences in terms
of costs and outcomes. The univariate sensitivity analysis showed that the results were not sensitive to
assumptions made, and the probabilistic sensitivity analysis indicated that the probability that the use of
fresh blood was cost-effective was close to the probability that standard-aged blood was cost-effective.
The findings mean that there is no reason to prefer fresh blood to standard-aged blood on the basis of
differences in quality or length of life, or on cost grounds.
0.0
0.2
0.4
0.6
0.8
1.0
Pr
o
b
ab
ili
ty
 f
re
sh
 b
lo
o
d
 is
co
st
-e
ff
ec
ti
ve
 v
s.
 s
ta
n
d
ar
d
-a
g
ed
 b
lo
o
d
0 10 20 30 40 50
Maximum willingness to pay for a QALY (UK, £000)
FIGURE 9 Cost-effectiveness acceptability curve showing the probability that fresh blood is cost-effective vs.
standard-aged blood at different values of the maximum willingness to pay for a QALY.
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TABLE 16 Univariate sensitivity analysis
Scenario
INMB (£), mean (95% CI)
20,000 30,000
Base case 25 (–4587 to 4637) –77 (–4821 to 4666)
Unit cost of fresh blood increased by 25% –142 (–4919 to 4636) –257 (–5171 to 4658)
Unit cost of standard-aged blood increased by 25% 269 (–4375 to 4914) 208 (–4579 to 4994)
Daily cost of non-invasive and invasive MV increased by 25% 272 (–4692 to 5236) 175 (–4909 to 5260)
Daily cost of non-invasive and invasive MV decreased by 25% –126 (–4441 to 4190) –216 (–4677 to 4244)
Daily cost of vasopressor and inotropes increased by 25% 244 (–4313 to 4800) 155 (–4532 to 4841)
Daily cost of vasopressor and inotropes decreased by 25% 91 (–4411 to 4593) 1.7 (–4634 to 4637)
Daily cost of CRRT, haemodialysis and peritoneal dialysis increased by 25% 212 (–4394 to 4818) 134 (–4597 to 4866)
Daily cost of CRRT, haemodialysis and peritoneal dialysis decreased by 25% 26 (–4513 to 4565) –55 (–4743 to 4632)
Daily cost of ICU admission increased by 25% 142 (–5082 to 5367) 50 (–5293 to 5394)
Daily cost of ICU admission decreased by 25% 186 (–4498 to 4870) 84 (–4732 to 4900)
Daily cost of inpatient stay increased by 25% 204 (–4927 to 5336) 95 (–5154 to 5344)
Daily cost of inpatient stay decreased by 25% 190 (–4403 to 4782) 82 (–4615 to 4778)
Note
Costs are in 2015 UK pounds.
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Chapter 6 A nested study comparing the EuroQol-5
Dimensions utility scores in critical care survivors
Background and aims
Health-related quality of life is an important outcome in critical care survivors. The EQ-5D is a generic
measure of HRQoL that allows the calculation of QALYs for undertaking cost–utility analyses. This is a
recommended measure of HRQoL in critical care45 and it has been used in critical care trials.46–48 Until
recently, the EQ-5D-3L has been commonly used, in which each dimension in the descriptive system is
assessed using three levels of severity. In order to reduce ceiling effects (the proportion of respondents
reporting the best possible health) and to increase sensitivity to changes and differences in health status,
the EQ-5D-5L was developed.49 Several studies have compared the EQ-5D-3L and the EQ-5D-5L in different
countries in both general population samples and specific patient groups, but none of these has examined
the two measures in critical care patients.49–59 The aim of the present study was to compare EQ-5D-3L
scores with EQ-5D-5L scores in critical care survivors in the UK. The sample for the present study comprised
359 patients treated at any of the 20 participating UK centres.
Methods
Measures
The EQ-5D utility scores were measured among survivors at 6 and 12 months post randomisation. Patients
at 10 centres were assigned to receive the EQ-5D-3L (165 randomised patients) and those at the other
10 centres received the EQ-5D-5L (194 randomised patients). The EQ-5D descriptive system contains five
dimensions (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression). For each
dimension, there are three levels in the EQ-5D-3L (no problems, some problems and unable to/extreme
problems) and five levels in the EQ-5D-5L (no problems, slight problems, moderate problems, severe problems
and unable to/extreme problems). Each EQ-5D-3L health state was converted into a single summary index
(utility score), applying a formula that attaches weights to each of the levels in each dimension based on
valuations by general population samples. Given the perspective of our analysis, we used a value set for the
UK population to calculate utility values at each time point for every participant.60 Each EQ-5D-5L health
state was similarly converted into a utility score using a recently published value set for England.30 For both
measures, utility scores of 1 represent full health, scores of zero are equivalent to death, negative scores
represent states worse than death. With the value set we have applied, the EQ-5D-3L has values that range
from 1 for no problems on any dimension to –0.594 for the worst health state (level-3 problems on every
dimension); the EQ-5D-5L has values ranging from 1 to –0.281 (level-5 problems on every dimension).
Statistical analysis
The mean and median scores of both measures at 6 and 12 months were calculated. We tested for
unadjusted differences in means between the two measures using two-sample t-tests. The distribution of
both measures was plotted, and visual inspection of the distributions suggested that the use of classical
parametric tests to compare the two sets of utility scores may not be appropriate. Therefore, we also
used the two-sample Wilcoxon rank-sum (Mann–Whitney) test and the two-sample median test to test
differences in distributions and medians.
Different patients completed the two measures, and to reduce the probability that differences in utility
scores were attributable to differences in patient characteristics, we ran adjusted analyses controlling for
treatment allocation (standard-aged blood, fresh blood), age (six categories), sex, comorbidities at hospital
admission [separate indicators for pre-existing significant comorbid illnesses comprised severe lung disease
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with symptoms at rest, previous myocardial infarction, severe heart disease with symptoms at rest,
disabling stroke, chronic renal failure (dialysis dependent), type 1 or 2 diabetes mellitus with evidence
of end-organ damage, metastatic cancer, immunosuppressive therapy, chronic institutionalisation for
> 6 months, deep-vein thrombosis], APACHE II score on ICU admission and MODS score on ICU admission.
We tested for differences in characteristics between patients receiving each EQ-5D utility measure at each
time point; for continuous variables we used two-sample t-tests, and for categorical variables we used
chi-squared tests. We regressed utility scores at 6 months and at 12 months (two separate regressions)
against an indicator for whether or not the patient had completed the EQ-5D-5L (1 = yes; 0 = otherwise)
plus the covariates. We used both ordinary least squares (OLS) regression (whereby the objective is to
estimate the conditional mean of the dependent variable) and median regression (to estimate the
conditional median).
We tested for floor and ceiling effects based on the proportion of patients reporting the best and worst
health states on the two versions [state 11111 (best) and state 33333 (worst EQ-5D-3L state) or 55555
(worst EQ-5D-5L state)]. We tested for differences in the proportions of patients reporting the best and
worst health states on the two versions at each time point using chi-squared tests.
To determine the extent of variation in utility scores according to respondent characteristics, we analysed
utility scores separately by age (higher or lower than the median age of 64 years), sex, the 10 individual
comorbidities, APACHE II score on ICU admission and MODS score on ICU admission. We regressed utility
score against each characteristic, also controlling for treatment allocation. For each of the 14 characteristics,
we ran eight (2 × 2 × 2) regressions, running separate models for each combination of EQ-5D version, time
(6 months and 12 months) and regression model (OLS and median regression); we ran 112 models in total.
We also explored whether or not the impact of treatment allocation (fresh blood or standard-aged blood) on
HRQoL was different using the two EQ-5D measures at both time points. We calculated mean and median
scores of the two measures at 6 and 12 months for each treatment group, and tested for unadjusted
differences between treatment groups with each measure at each time point. We tested for adjusted
differences using OLS and median regression, regressing utility scores at 6 months and at 12 months with
both EQ-5D measures (four separate regressions) against the covariates (including treatment allocation).
Robust standard errors are reported throughout and p-values of < 0.05 were considered statistically
significant. All analyses were undertaken using Stata® version 13 (StataCorp LP, College Station, TX, USA).
Results
In total, 227 of the 359 patients were alive at 6 months, and, of these, 121 returned an EQ-5D questionnaire
(53%). A total of 221 patients were alive at 12 months, and 119 returned a questionnaire (54%). The
distribution of both sets of utility scores at each time point was wide and discontinuous (Figures 10–13).
The mean utility scores at 6 months for the EQ-5D-3L and EQ-5D-5L were 0.51 (SD 0.37) and 0.58 (SD 0.31),
respectively (Table 17). The median utility scores were 0.59 (IQR 0.19–0.73) and 0.65 (IQR 0.34–0.82),
respectively. At 12 months, the mean values were 0.50 (SD 0.33) and 0.60 (SD 0.33), respectively, and the
median values were 0.62 (IQR 0.19–0.69) and 0.70 (IQR 0.42–0.84), respectively. The means, distributions
and medians were not significantly different at 6 months (all p-values were ≥ 0.22), and neither was the
mean difference at 12 months (p = 0.11), but the differences in distributions and medians at 12 months were
significant (both p-values= 0.03).
There were no differences in observed characteristics between patients receiving the two utility measures
at each time point, with the exception that a higher proportion of respondents in the EQ-5D-3L group
at 12 months had been allocated to receive fresh blood than that of the EQ-5D-5L group (p = 0.04;
Table 18).
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FIGURE 10 Distribution of EQ-5D-3L utility scores at 6 months.
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FIGURE 11 Distribution of EQ-5D-5L utility scores at 6 months.
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FIGURE 12 Distribution of EQ-5D-3L utility scores at 12 months.
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After adjusting for patient characteristics, there were no significant differences between the conditional
mean and median EQ-5D-3L and EQ-5D-5L utility scores at 6 months (p ≥ 0.17; Table 19), but there were
significant differences at 12 months (p < 0.05); mean EQ-5D-5L scores were 0.15 units higher with the
EQ-5D-5L than with the EQ-5D-3L, and median EQ-5D-5L scores were 0.20 units higher.
No patients reported being in the worst EQ-5D-3L state or the worst EQ-5D-5L state at 6 or 12 months.
Eight patients (15%) reported being in the best health state on the EQ-5D-3L at 6 months compared with
six patients (9%) on the EQ-5D-5L. Seven patients (14%) reported being in the best health state on the
EQ-5D-3L at 12 months compared with six patients (9%) on the EQ-5D-5L. These figures were not
significantly different (p ≥ 0.29).
TABLE 17 Descriptive statistics for EQ-5D-3L and EQ-5D-5L utility scores at 6 and 12 months
Variable
Time point
6 months 12 months
EQ-5D-3L
Number of observations 53 49
Mean (SD) 0.51 (0.37) 0.50 (0.33)
Median (IQR) 0.59 (0.19–0.73) 0.62 (0.19–0.69)
EQ-5D-5L
Number of observations 68 70
Mean (SD) 0.58 (0.31) 0.60 (0.33)
Median (IQR) 0.65 (0.34–0.82) 0.70 (0.42–0.84)
Tests of differences (unadjusted), p-value
Difference in meansa 0.22 0.11
Difference in distributionsb 0.25 0.03
Difference in mediansc 0.22 0.03
a Two-sample t-test.
b Two-sample Wilcoxon rank-sum (Mann–Whitney) test.
c Two-sample median test.
Pe
rc
en
ta
g
e
– 0.2 0.0 0.2 0.4 0.6 0.8 1.0
EQ-5D-5L utility score (n = 70)
0
5
10
15
FIGURE 13 Distribution of EQ-5D-5L utility scores at 12 months.
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TABLE 18 Patient characteristics
Variable
Time point
6 months 12 months
EQ-5D-3L
(n= 53)
EQ-5D-5L
(n= 68)
Tests of
differences
(p-value)
EQ-5D-3L
(n= 49)
EQ-5D-5L
(n= 70)
Tests of
differences
(p-value)
Allocated to receive fresh blood (%) 53 43 0.27 59 40 0.04
Age (years), mean (SD) 59 (15) 61 (15) 0.60 59 (17) 59 (16) 0.92
Male (%) 58 54 0.65 55 57 0.83
Severe lung disease with symptoms at
rest (%)
8 7 0.97 6 7 0.83
Previous myocardial infarction (%) 9 15 0.38 8 14 0.31
Severe heart disease with symptoms at
rest (%)
6 7 0.72 6 7 0.83
Disabling stroke (%) 0 1 0.38 0 0
Chronic renal failure [dialysis
dependent (%)]
0 4 0.12 0 4 0.14
Type 1 or 2 diabetes mellitus with
evidence of end-organ damage (%)
9 15 0.38 8 14 0.31
Metastatic cancer (%) 2 4 0.44 0 6 0.09
Immunosuppressive therapy (%) 4 9 0.27 4 11 0.16
Chronic institutionalisation for
> 6 months (%)
2 1 0.86 2 3 0.78
Deep-vein thrombosis (%) 6 1 0.20 4 3 0.72
APACHE II score (points), mean (SD) 26 (8) 23 (7) 0.14 25 (8) 23 (7) 0.19
MODS score (points), mean (SD) 5 (3) 5 (3) 0.51 5 (3) 5 (3) 0.73
TABLE 19 Adjusted differences in mean and median EQ-5D-3L and EQ-5D-5L utility scores at 6 and 12 months
Variable
Time point
6 months 12 months
OLS
Marginal effect (95% CI; p-value) 0.10 (–0.04 to 0.23; 0.17) 0.15 (0.02 to 0.28; 0.02)
R2 0.16 0.12
Number of observations 121 119
Median regression
Marginal effect (95% CI; p-value) 0.10 (–0.06 to 0.26; 0.22) 0.20 (0.09 to 0.30; < 0.01)
Pseudo-R2 0.11 0.10
Number of observations 121 119
The marginal effect in the OLS models is the adjusted difference in mean EQ-5D-5L utility scores minus EQ-5D-3L utility
scores. The marginal effect in the median regression is the adjusted difference in medians. Controls are included but not
reported for treatment allocation, age, sex, comorbidities, APACHE II score and MODS score.
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For the 112 regression models used to determine the extent of variation in utility score according to
patient characteristics, in only three models was the coefficient on the patient characteristic significantly
different from zero. In all three cases, the significant effect was found using the EQ-5D-5L in patients at
the 12-month follow-up using median regression (sample size: n = 70 patients). These analyses showed
that immunosuppressive therapy, chronic institutionalisation for > 6 months and deep-vein thrombosis
had a significant negative impact on median EQ-5D scores; the marginal effects were –0.23 (95% CI
–0.47 to –0.01; p-value = 0.05; number of patients with condition, 8), –0.68 (95% CI –1.22 to –0.13;
p-value = 0.02; number of patients with condition, 2) and –0.87 (95% CI –1.42 to –0.31; p-value = 0.01;
number of patients with condition, 2), respectively.
At 6 months, there were no unadjusted differences in utility scores (means, distributions and medians) between
trial treatment groups using either the EQ-5D-3L or the EQ-5D-5L (p≥ 0.13; Table 20). At 12 months, there
were no unadjusted differences in utility scores between treatment groups using the EQ-5D-3L (p≥ 0.40),
but EQ-5D-5L distributions were significantly different between treatment groups (p-value of –0.03). When we
controlled for patient characteristics, there were no significant differences in utility scores between treatment
groups for either EQ-5D measure at either time point (p≥ 0.20; Table 21).
TABLE 20 Unadjusted EQ-5D-3L and EQ-5D-5L utility scores at 6 and 12 months by treatment group
Time point
Trial group
Tests of differences
(unadjusted)Fresh blood Standard-aged blood
6 months
EQ-5D-3L
Number of observations 28 25
Mean (SD) 0.45 (0.43) 0.57 (0.28) p= 0.24a
Median (IQR) 0.55 (0.08–0.78) 0.59 (0.52–0.71) p= 0.55b
p= 0.87c
EQ-5D-5L
Number of observations 29 39
Mean (SD) 0.63 (0.31) 0.54 (0.30) p= 0.26a
Median (IQR) 0.74 (0.50–0.82) 0.54 (0.28–0.83) p= 0.19b
p= 0.14c
12 months
EQ-5D-3L
Number of observations 29 20
Mean (SD) 0.47 (0.35) 0.55 (0.31) p= 0.46a
Median (IQR) 0.59 (0.08–0.69) 0.64 (0.26–0.69) p= 0.40b
p= 0.59c
EQ-5D-5L
Number of observations 28 42
Mean (SD) 0.70 (0.29) 0.54 (0.33) p= 0.05a
Median (IQR) 0.76 (0.60–0.87) 0.66 (0.30–0.80) p= 0.03b
p= 0.06c
a Two-sample t-test.
b Two-sample Wilcoxon rank-sum (Mann–Whitney) test.
c Two-sample median test.
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Summary
In conclusion, this study compared the performance of the EQ-5D-3L and the EQ-5D-5L in measuring the
HRQoL in critical care survivors in the UK. There was some evidence of difference between the two
measures, and that the EQ-5D-5L discriminated between subgroups of patients with major comorbidities
whereas the EQ-5D-3L did not, but further research is needed to confirm these findings.
TABLE 21 Adjusted differences in mean and median EQ-5D-3L and EQ-5D-5L utility scores at 6 and 12 months by
treatment group
Time point
Score
EQ-5D-3L EQ-5D-5L
6 months
OLS
Marginal effect (95% CI; p-value) –0.10 (–0.33 to 0.12; 0.37) 0.06 (–0.10 to 0.23; 0.47)
R2 0.44 0.24
Number of observations 53 68
Median regression
Marginal effect (95% CI; p-value) –0.11 (–0.45 to 0.24; 0.53) 0.07 (–0.23 to 0.37; 0.64)
Pseudo-R2 0.35 0.22
Number of observations 53 68
12 months
OLS
Marginal effect (95% CI; p-value) 0.03 (–0.17 to 0.23; 0.76) 0.13 (–0.07 to 0.33; 0.20)
R2 0.45 0.15
Number of observations 49 70
Median regression
Marginal effect (95% CI; p-value) 0.05 (–0.43 to 0.53; 0.84) 0.12 (–0.12 to 0.37; 0.31)
Pseudo-R2 0.35 0.09
Number of observations 49 70
The marginal effect in the OLS models is the adjusted difference in mean utility scores by treatment allocation group (fresh
blood minus standard-aged blood). The marginal effect in the median regression is the adjusted difference in median utility
scores. Controls are included but not reported for treatment allocation, age, sex, comorbidities, APACHE II score and
MODS score.
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Chapter 7 An analysis of the UK Age of BLood
Evaluation trial data set to explore factors associated
with costs and quality-adjusted life-years in critically
ill adults
Background and aims
Intensive care units provide potentially life-saving interventions to critically ill patients, but incur considerable
costs when treating patients.61 Length of stay is a driver of ICU costs, and factors affecting this include
institutional factors (such as organisational structure and resources), medical factors (especially cause of
admission and severity of illness) and psychosocial factors (such as communication between clinical staff,
and with the patient’s family).62 On discharge from the ICU, survivors often have long-term health problems
that affect their quality of life and survival, and health service utilisation and costs; factors associated with
increased resource use include increasing age, comorbidities, organ dysfunction score and previous resource
use.15,61 The aim of the present study was to investigate the factors associated with hospital costs and total
costs and QALYs up to 12 months after ICU admission in critically ill adults in the UK.
Methods
The sample for the present study comprised 359 patients treated at any of the 20 participating UK centres.
Two patients had no study measurements and so were not included in the analysis, giving a sample of
357 patients.
Outcome measures
Utilities and quality-adjusted life-years
Generic health status was described at 6 and 12 months post randomisation using the EQ-5D descriptive
system.29,39 This contains five dimensions (mobility, self-care, usual activities, pain and discomfort, and
anxiety and depression). UK study centres were randomised to use of either the EQ-5D-3L or the EQ-5D-5L
at both follow-up time points. For each dimension, there are three levels in the EQ-5D-3L (no problems,
some problems and unable to/extreme problems) and five levels in the EQ-5D-5L (no problems, slight
problems, moderate problems, severe problems and unable to/extreme problems). As patients recruited to
the trial were initially critically ill, completion of the EQ-5D at randomisation was not possible. Therefore,
baseline utility was assumed to be zero for all patients. This assumption has been made in previous studies
where baseline utility measurement was not possible.40 EQ-5D health states were converted into utility
values using formulae that attach weights to each level in each dimension based on valuations by general
population samples. Different formulae and value sets were used to calculate utility values for the EQ-5D-3L
and the EQ-5D-5L, although both value sets were based on the UK general population.30,41 Utility values of
1 represent full health, values of zero are equivalent to death and negative values represent states worse
than death. Patients who died were assigned a utility value of zero at all subsequent time periods. A utility
profile was constructed for every patient, assuming a straight-line relation between their utility values at
each measurement point. QALYs for every patient from baseline to 12 months were calculated as the area
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under the utility profile. The implications of our assumptions were as follows. For patients who survived up
to 6 months, QALYs up to 6 months were calculated using the EQ-5D scores at 6 months, assuming an
EQ-5D score of zero units at baseline, and a linear interpolation between baseline and 6 months. For
patients who died between baseline and 6 months, we assumed that they accrued zero QALYs. For patients
who survived up to 12 months, we used a linear interpolation between EQ-5D scores at 6 and 12 months.
For patients who died between 6 and 12 months and for whom an EQ-5D score at 6 months was available,
a linear interpolation was applied between the 6-month EQ-5D score and the date of death, at which point,
a EQ-5D score of zero units was applied thereafter. The maximum QALYs achievable in the study were 0.75.
We assigned all the EQ-5D data that were collected to either the 6- or 12-month measurement points,
irrespective of the precise time when these were actually measured.
Resource use and costs
The analysis took a UK NHS and personal social services perspective.32 Costs were calculated in 2015 UK
pounds and inflated where necessary.33 For every patient, we calculated the cost of the index hospitalisation
(from hospital admission to hospital discharge) and of follow-up to 12 months based on resource use data
collected in the trial. We included the costs of blood transfusions; fresh-frozen plasma and platelets; length
of stay in hospital regular inpatient wards and in the ICU; and use of MV, vasopressors, inotropes, CRRT,
haemodialysis and peritoneal dialysis in the ICU. Post-discharge costs included GP visits in the clinic and at
home, and telephone consultations; district and practice nurse visits; physiotherapist, occupational therapist
and speech and language therapist visits; dietitian, home care worker (e.g. Meals on Wheels), social worker,
psychological therapist, counsellor, and aids and adaptation worker visits; specialist nurse visits (substance
misuse nurses, Macmillan Cancer Support nurses); day hospital visits; A&E visits; outpatient appointments;
and readmissions to hospital, including surgical procedures and ICU spells. Unit costs were obtained
from published sources and inflated where appropriate (see Chapter 5 for further details about costing
methodology and the unit costs used). The unit costs per unit of fresh blood and standard-aged blood were
assumed to be the same. Unit costs of hospital inpatient and ICU stays were daily costs applied to length of
stay data collected in the trial. Given the time horizon, discounting was not applied to costs (or outcomes).
Statistical analysis
Outcome measures and samples
We ran seven sets of regression models, with outcomes and samples described in Table 22. We ran models
for utilities measured at 6 and 12 months on survivors only, as including zero values for those who died
would not be informative (132 patients died before 6 months, and six patients died between 6 and
12 months). Similarly, we examined costs of follow-up to 12 months for survivors only.
TABLE 22 Outcome measures and samples
Model Outcome measure Sample
1 EQ-5D score at 6 months Survivors only
2 EQ-5D score at 12 months Survivors only
3 QALYs up to 12 months Survivors only
4 QALYs up to 12 months All patients (survivors plus those who died)
5 Costs of index admission All patients (survivors plus those who died)
6 Costs of follow-up Survivors only
7 Total costs (index admission plus follow-up) All patients (survivors plus those who died)
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Covariates
We included the following variables as covariates in the regression models: age (linear term), sex,
comorbidities at hospital admission [separate indicators for pre-existing significant comorbid illnesses
comprising severe lung disease with symptoms at rest, previous myocardial infarction, severe heart disease
with symptoms at rest, disabling stroke, chronic renal failure (dialysis dependent), type 1 or 2 diabetes
mellitus with evidence of end-organ damage, metastatic cancer, immunosuppressive therapy, chronic
institutionalisation for > 6 months, deep-vein thrombosis], APACHE II score on ICU admission and lowest
MODS score during ICU stay, treatment allocation (fresh blood or standard-aged blood) and study centre.
We did not include separate controls for whether or not patients completed the EQ-5D-3L or the EQ-5D-5L
measure, as this was determined by study centre. Covariates measured after baseline assessment were
not included in the analyses, because these may have been influenced by the costs incurred and utilities
accrued. In models that included all patients (models 4, 5 and 7), we also included covariates for whether
or not the patient died in the ICU or during follow-up. Previous studies have shown that important
drivers of ICU and post-discharge costs are cause of admission and severity of illness, age and pre-existing
comorbidities.15,62,63 To reflect this we included age, pre-existing significant comorbid illnesses and illness
severity measured by APACHE II score and MODS score in our analyses.
Regression models
For utility scores and QALYs, we used both OLS regression (whereby the objective is to estimate the
conditional mean of the dependent variable) and median regression (to estimate the conditional median).
For costs, to account for skewness of the cost data, we used a generalised linear model with gamma
family and log-link.64 We also considered using log-normal, Gaussian, inverse Gaussian and negative
binomial distributions, but the gamma model gave the best fit in terms of residual plots and the Akaike
information criterion.
Dealing with missing data
The extent of missing data for some of the outcome measures included in the analysis was large (the
range across the seven measures was 1–56%). Multiple imputation was used to impute missing data
separately for each outcome. For analyses using survivors only (models 1, 2, 3 and 6), age, sex, study
centre, treatment allocation, comorbidities at hospital admission, APACHE II score on ICU admission and
worst MODS score during ICU stay were included in the imputation as additional explanatory variables
(these were variables in the trial data set with no missing values). For analyses using all patients (models 4,
5 and 7), we additionally included whether or not the patient died in the ICU or during follow-up. For
utility scores and QALYs among survivors only (models 1, 2 and 4), we imputed utility scores at 6 and
12 months for survivors only and calculated QALYs up to 12 months from the imputed values. We repeated
this approach to impute QALYs up to 12 months for all patients, but did not limit the sample to survivors
only (model 3). We imputed each of the cost measures directly, and for follow-up costs to 12 months
(model 6), we ran the imputation procedure on survivors only, whereas for index hospitalisation costs and
total costs up to 12 months (models 5 and 7), we included all patients. We used an iterative Markov chain
Monte Carlo procedure based on multivariate normal regression, generating 20 imputed data sets. We ran
the regression model described above on each of the imputed data sets and computed aggregate
coefficients and standard errors using combination rules.65
Variable selection
Each of the outcome measures was regressed against the covariates. The predictors of each outcome
were selected using forward and backward stepwise selection techniques, and only statistically significant
variables were retained after each iteration. We also ran univariate models for every outcome measure,
including each covariate individually. Study centre was included in every model. Robust standard errors are
reported throughout and p-values of < 0.05 were considered statistically significant. All analyses were
undertaken using Stata version 13.
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Results
In total, 219 of the 357 patients were alive at 12 months, and, of these, 121 returned an EQ-5D questionnaire
at 6 months (55% of survivors) and 119 at 12 months (54%). Data on QALYs up to 12 months were available
for 96 patients (44%). Including those patients who died, QALY data up to 12 months were available for
228 patients (64% of all patients). The distribution of utility scores at each time point and QALYs up to
12 months was wide and discontinuous (Figures 14–17). The high frequency of zero values in QALYS up to
12 months across all patients reflects the number of patients who died before 6 months (132 patients). The
mean utility scores at 6 and 12 months were 0.54 (SD 0.33) and 0.56 (SD 0.33), respectively (Table 23). The
medians were 0.62 (IQR 0.28–0.80) and 0.66 (IQR 0.31–0.80), respectively. Mean and median QALYs up to
12 months across all patients were 0.18 (SD 0.26) and 0 (IQR 0–0.40), again reflecting the number of patients
who died before 6 months. Values for survivors only were 0.43 (SD 0.23) and 0.46 (IQR 0.27–0.59), respectively.
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FIGURE 14 Distribution of utility scores at 6 months (survivors only).
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FIGURE 15 Distribution of utility scores at 12 months (survivors only).
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Index hospitalisation costs were available for 352 patients (99% all patients), and the mean and median
values were £30,803 (SD £20,501) and £26,771 (IQR £15,974–39,744), respectively. Follow-up costs to
12 months were available for 108 survivors (49% of survivors), with mean and median values of £8324
(SD £11,908) and £3819 (IQR £1549–10,617), respectively. Total costs up to 12 months across all patients
had mean and median values of £31,867 (SD £21,130) and £26,972 (IQR £16,073–41,590), respectively.
The distribution of all three cost variables was positively skewed (Figures 18–20).
The mean age of patients was 62 years and 53% were male (see Table 23). The prevalence of pre-existing
significant comorbid illnesses ranged from 1% (disabling stroke, chronic institutionalisation for > 6 months)
to 11% (type 1 or 2 diabetes mellitus with evidence of end-organ damage). The mean APACHE II score at
ICU admission was 25 points (SD 7 points) and the mean worst MODS score during ICU stay was 7 points
(SD 3 points), with the modal category 5–8 points (50% of patients). Twenty-five per cent of patients died
during the ICU stay, and 39% died by the end of the 12-month follow-up.
None of the covariates was a statistically significant predictor of utility scores at 6 or 12 months or of
QALYs up to 12 months, either for all patients or survivors only (models 1–4; results not shown).
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FIGURE 16 Distribution of QALYs up to 12 months (all patients).
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FIGURE 17 Distribution of QALYs up to 12 months (survivors only).
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TABLE 23 Descriptive statistics
Variable Value Observations Missing (%)
Dependent variables
Utility scores at 6 months (survivors only)
Mean (SD) 0.54 (0.33) 121 45
Median (IQR) 0.62 (0.28–0.80) 121 45
Utility scores at 12 months (survivors only)
Mean (SD) 0.56 (0.33) 119 46
Median (IQR) 0.66 (0.31–0.80) 119 46
QALYs up to 12 months (all patients)
Mean (SD) 0.18 (0.26) 228 36
Median (IQR) 0 (0–0.40) 228 36
QALYs up to 12 months (survivors only)
Mean (SD) 0.43 (0.23) 96 56
Median (IQR) 0.46 (0.27–0.59) 96 56
Index hospitalisation costs (all patients)
Mean (SD) 30,803 (20,501) 352 1
Median (IQR) 26,771 (15,974–39,744) 352 1
Follow-up costs to 12 months (survivors only)
Mean (SD) 8324 (11,908) 108 51
Median (IQR) 3819 (1549–10,617) 108 51
Total costs up to 12 months (all patients)
Mean (SD) 31,867 (21,130) 218 39
Median (IQR) 26,972 (16,073–41,590) 218 39
Independent variables (all patients)
Age (years), mean (SD) 61.5 (16.3) 357 0
Male (%) 53.2 357 0
Severe lung disease with symptoms at rest (%) 7.6 357 0
Previous myocardial infarction (%) 10.9 357 0
Severe heart disease with symptoms at rest (%) 8.1 357 0
Disabling stroke (%) 1.1 357 0
Chronic renal failure (dialysis dependent) (%) 4.2 357 0
Type 1 or 2 diabetes mellitus with evidence of
end-organ damage (%)
11.2 357 0
Metastatic cancer (%) 2.0 357 0
Immunosuppressive therapy (%) 7.6 357 0
Chronic institutionalisation for > 6 months (%) 1.1 357 0
Deep-vein thrombosis (%) 2.8 357 0
APACHE II score (points), mean (SD) 24.6 (7.3) 357 0
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TABLE 23 Descriptive statistics (continued )
Variable Value Observations Missing (%)
Worst MODS score (points) during ICU stay,
mean (SD)
7.0 (3.3) 357 0
0–4 (%) 23.8 85 –
5–8 (%) 50.0 178 –
9–12 (%) 19.9 71 –
≥ 13 (%) 6.4 23 –
Died in ICU (%) 25.2 357 0
Died in ICU or during 12-month follow-up (%) 38.9 357 0
Notes
Costs are in 2015 UK pounds.
The ‘missing (%)’ column shows the number of missing data for each variable included in the analysis across the 219
survivors or all 357 patients (survivors plus those who died).
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FIGURE 18 Distribution of index hospitalisation costs (all patients).
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FIGURE 19 Distribution of follow-up costs up to 12 months (survivors only).
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Index hospitalisation costs were predicted by worst MODS score during ICU stay and whether or not the
patient died in the ICU (Table 24). Controlling for whether or not the patient died, hospitalisation costs
increased with worsening MODS score; patients with a MODS score of 5–8 points incurred around
£10,000 higher mean costs than those with values of 0–4 points, and those patients with scores of
≥ 9 points incurred mean costs that were £16,000–19,000 higher than those with scores of 0–4 points
(note that the values for the 9- to 12-point and ≥ 13-point categories were not significantly different from
one another). Patients who died incurred, on average, £18,000 lower costs than those who did not die,
depending on their MODS score. Survivors with prior chronic institutionalisation incurred costs during
the 12 months’ follow-up that were, on average, around £24,000 higher than those without chronic
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FIGURE 20 Distribution of total costs up to 12 months (all patients).
TABLE 24 Factors associated with index hospitalisation costs, follow-up costs to 12 months and total costs up to
12 months
Sample
Index hospitalisation
costs
Follow-up costs to
12 months
Total costs up to
12 months
All patients Survivors only All patients
Worst MODS score (points) during ICU
stay: 5–8 points
0.32 (< 0.01; £9989) – 0.26 (0.03; £8345)
Worst MODS score (points) during ICU
stay: 9–12 points
0.61 (< 0.01; £18,672) – 0.54 (< 0.01; £18,527)
Worst MODS score (points) during ICU
stay: ≥ 13 points
0.53 (< 0.01; £16,311) – 0.51 (< 0.01; £21,207)
Died in ICU –0.58 (< 0.01; –£17,850) – –0.68 (< 0.01; –£29,771)
Chronic institutionalisation for
> 6 months
– 1.29 (< 0.01; £24,137) 0.86 (< 0.01; £36,889)
Number of observations 357 219 357
Notes
Costs are in 2015 UK pounds.
Data include values imputed using multiple imputation (see Dealing with missing data).
Values shown are coefficients (p-values; marginal effects). The marginal effects are the change in costs vs. the omitted
category; for worst MODS score during ICU admission, the omitted category is 0–4 points; for died in ICU, the omitted
category is did not die in ICU; for chronic institutionalisation for > 6 months, the omitted category is not institutionalised for
> 6 months.
ANALYSIS OF THE UK ABLE TRIAL DATA SET: COSTS AND QUALITY-ADJUSTED LIFE-YEARS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
62
institutionalisation. In the model of total costs up to 12 months, the following covariates were significant:
costs were higher with worsening MODS score for those who died in the ICU and those with prior chronic
institutionalisation. Controlling for whether or not the patient died, total costs increased with worsening
MODS score by, on average, around £8000, £19,000 and £21,000 per patient for those with scores of
5–8, 9–12 and ≥ 13 points, respectively, compared with those with a score of 0–4 points. On average,
those who died incurred £30,000 lower costs than those who did not, and those with prior chronic
institutionalisation incurred total costs that were, on average, around £24,000 higher than those without
chronic institutionalisation. None of the other covariates was individually statistically significant as a
predictor of any of the cost measures, nor were they jointly significant when added to the models
just described.
Summary
We evaluated the factors associated with hospital costs and total costs and QALYs up to 12 months after
ICU admission in critically ill adults in the UK. None of the variables in our data was a significant predictor
of utility scores at 6 or 12 months, or of QALYs up to 12 months. The lack of an effect may reflect the
limitations of our data set in terms of available measures, sample size and data missingness. Consistent
with previous studies, we found that ICU costs were an increasing function of illness severity, measured in
terms of MODS score and mortality.62 Contrary to previous studies, costs from hospital discharge up to
12 months were largely unaffected by acute illness factors, age or comorbidities; however, there was some
evidence that chronic institutionalisation, included as an indicator of pre-existing morbidity, was associated
with 12-month costs.15,63
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Chapter 8 Discussion and implications for
future practice
Study conduct
The ABLE UK study was specifically funded to collaborate with the Canadian ABLE trial [funded by the
Canadian Institutes of Health Research (CIHR)]. Specifically, the aim was to ensure the recruitment of
the intended sample size of 2510 patients, and to include a UK-specific health economic evaluation.
At the time of funding, Canadian recruitment was slower than anticipated and there was a risk that the
trial would not achieve the target sample, which would have significantly reduced its external validity,
generalisability and impact. Funding by the HTA programme, together with recruitment in France and the
Netherlands, meant that recruitment was completed to target.
There were several relevant learning issues from this model of funding. First, despite the HTA programme
‘fast-tracking’ the application following the commissioned call, the process of review and final funding,
followed by contract finalisation, meant that the ABLE UK trial came ‘on-line’ almost 2 years after recruitment
to the international trial began. The further time required to set up recruitment in the UK further delayed
contribution to the main trial. Second, several practical issues resulted from the international arrangements:
collaboration and data sharing agreements were needed between the UK and Canada; separate sponsorship
arrangements for the UK were required; and the trial protocol required adaptation to the UK, mainly as a
result of different legal frameworks for the inclusion of incapacitated patients. Third, the legal and contractual
burden for the trial was very high as a result of the multiple stakeholders, which created a significant
workload for the sponsor and delays in trial set-up, despite attempts to expedite delays. Of relevance,
there was no funding allocated to the very high legal/contracting burden for the sponsor (the University of
Edinburgh). The consequence of these issues was that, despite intense effort by the trial management team,
the set-up time to start recruitment meant that approximately 40% of the international trial sample size had
been achieved before UK recruitment began. The recruitment rates in the UK were close to those predicted,
and comparable to non-UK centres, but the international sample size was achieved before the UK target of
500 (revised to 400 during the trial) was achieved. A consequence was a risk that insufficient longer-term
outcome data would be available for the health economic evaluation. Through collaboration between the
international trial team, UK funder, sponsor and ethics committees, we were able to gain approval to extend
recruitment in the UK until the database for the international cohort was locked for analysis. This approach
allowed us to maximise the use of funds in the UK and obtain a larger data set for economic evaluation.
These processes could have been improved and shortened if funding across international collaborators could
be considered in a more parallel approach, or the review process for commissioned research could be
shortened further once an international trial was under way. In addition, pre-agreed arrangements for
sponsorship, shared protocols and data governance between the NIHR and equivalent international funders
might have reduced delays and workload.
The UK ABLE trial was the first, to our knowledge, to require considerable research activity from blood bank
staff across multiple NHS sites. Blood banks were required to manage group allocation and blinding, which
involved implementation of study-specific SOPs and blood inventory management. We encountered several
challenges that resulted in significant delays and limited recruitment. First, some blood banks were managed
by the blood transfusion service, some by the NHS, and some were contracted partly/wholly to private
providers; this resulted in contractual and governance challenges that delayed agreements. Second, almost all
blood banks worked under intense pressure with staff shortages and competing activities that took priority
over research, notably inspections. As a result, and despite the provision of set-up funding and generous
per-patient remuneration, many blood banks were unable to complete training and site set-up procedures
in a timely manner, because they were unable to free up dedicated time for these activities. This occurred
DOI: 10.3310/hta21620 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 62
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Walsh et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
65
despite strong support from clinical and technical staff within centres, and enthusiasm to participate in the
trial. The nature of the work also required relatively senior staff to implement set-up and training, and the
group allocation procedures. Employing blood bank co-ordinators on the project management team, who
visited and supported all blood banks, was crucial in minimising these delays and ensuring governance issues
were addressed in a consistent manner. Our experience strongly supports the use of similar dedicated
individuals in any future trials involving extensive blood bank procedures across multiple sites. We would also
recommend identifying methods to protect blood bank staff time early in the trial to ensure set-up times are
minimised, as this was the most frequent cause of delays. Finding ways to enable blood bank procedures to
occur outside normal working hours would also have significantly increased recruitment, as this was the
reason for non-inclusion of otherwise eligible patients in 75% of cases.
The UK ABLE trial required recruitment of incapacitated patients in a time-sensitive manner, as decisions were
required within a few hours in order to avoid delays in blood transfusions that had been prescribed for clinical
reasons. This resulted in a high level of complexity in the consent procedures, which resulted in significant
resource use and limited recruitment. First, different approaches were required in England/Northern Ireland
versus Scotland, as a result of different mental capacity legislation. Specifically, in Scotland, patients could not
be included unless consent was obtained from a relative/welfare guardian prior to randomisation. This meant
that patients for whom a relative/welfare guardian was unavailable during the short recruitment window
could not be included in the trial. The provision for telephone consent was essential to decrease the impact of
this limitation. The experience of research staff, based on informal feedback, was that this was acceptable to
most relatives. In England/Northern Ireland, the ability to ask a professional consultee was available, which
reduced the pressure on research staff and made enrolment potentially easier. Experience during the trial
suggested that the English legislation improved efficiency and was easier to implement. In all cases (Scotland
and England/Northern Ireland), the intention was to discuss ongoing continuation in the trial with survivors
once they regained capacity. This was often many days/weeks after randomisation and after discharge from
the ICU, which required significant time commitment from research staff and was sometimes unsuccessful if
patients had been discharged home. There was only one withdrawal of consent for a patient who regained
capacity, suggesting that these processes were acceptable. After seeking clarification from the ethics
committee, we amended the protocol (amendment 4) to enable patients to be contacted after hospital
discharge with information and for consent to remain in the trial. This appeared to be acceptable to patients;
however, when no response was obtained, it meant that the patient remained in the trial based on the
agreement provided in hospital by the professional or personal consultee (England/Northern Ireland) or
relative/welfare guardian (Scotland). The complexity of these processes illustrates the ethics and governance
challenges of critical care research, even when the intervention and control group practices were all within
current routine care, as was the case in the trial. Our experience strongly supports the ability to use telephone
consent when appropriate (especially in Scotland), and the use of professional consultees when relatives were
not available (in England/Northern Ireland). Early clarification of procedures to be used when follow-on
consent is not obtained should also be considered in future similar research, including contact post hospital
discharge. Our experience also highlights the high resource costs of obtaining consent in critical care trials,
which should be recognised in funding applications.
We found the use of regular teleconferences with site representatives useful in maintaining enthusiasm,
recruitment rates and, especially, for identifying and sharing common problems and finding solutions.
The development of a ‘top tips’ resource and a summary of common blocks to recruitment and solutions
that worked well and less well was effective, especially as a ‘living’ document that was regularly updated
and circulated. The use of recruitment competitions and prizes for key milestones was also popular and
maintained the engagement of research nurses/co-ordinators who were key to ongoing patient identification.
Our experience supports the use of multiple strategies to support sites and maintain buy-in, which we believe
especially important in critical care trials, which are challenging at multiple levels.
Our experience confirms the challenges found in other critical care trials, which included long-term follow-up
for economic evaluation by obtaining questionnaire-based follow-up for up to 12 months. We achieved 61%
and 58% completed follow-up at 6 and 12 months, respectively, for questionnaires for surviving patients,
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which equated to 75% and 74% complete follow-up when death was included as an outcome, respectively.
This compared favourably with other recent UK-based critical care trials in which follow-up rates of 30–40%
were typical. After a single postal questionnaire, completion rates were only 48% and 49% at 6 and
12 months, respectively. We included a gift token with these questionnaires, which may have improved
responses, but this is difficult to assess. The use of a second questionnaire request (at 12 months only)
followed by attempted telephone contact improved response rates by 18–20%. Given the increasing interest
in longer-term HRQoL outcomes following critical illness, the recognition that these are significantly reduced in
many patients, and of their impact on QALYs and cost-effectiveness analysis, obtaining high follow-up rates
are important. Our data suggest that including a multifaceted strategy that includes both postal and
telephone-based methods, and costing the resources to undertake this, is important in future research. Our
embedded audit suggesting an average of 30 minutes per patient follow-up is useful for future grant-costing
in this population.
Clinical results
The results of the international ABLE trial were published in March 2015, before the UK ABLE trial follow-up
was completed.31 No significant effects (beneficial or harmful) were found from the use of fresh versus
standard-aged RBCs on mortality at 90 days, or any of the predefined secondary outcomes. These included
the duration of respiratory, cardiovascular and renal support, length of stay or any predefined AEs, especially
transfusion reactions. There were also no differences in outcomes within any of the predefined subgroups,
including medical, surgical and trauma admissions. Importantly, the RBC transfusion triggers used were
similar to those recommended in current guidelines11,66,67 and a large separation in RBC age was achieved
between the groups (mean 6.1 vs. 22.0 days). The standard-aged RBC group was similar to the RBC storage
age profile that is used in the NHS. A high rate of compliance with group allocation was achieved, and the
findings of sensitivity analyses that included only patients who received RBC transfusions and those that
included patients who received only RBCs with storage age according to group allocation were almost
identical. The study population had a very high illness severity based on their illness severity score, the
degree of organ failure at baseline and during the intervention, and the high mortality rate of 33% at
90 days. This observed control group mortality rate was higher than the 25% on which the sample size was
calculated for the international trial. However, the aim was to include patients with a mortality rate that was
at least 25%, such that the trial achieved recruitment of the target patient group. The mean length of ICU
and hospital stay of 14 days and 32 days, respectively, highlights the extremely high resource use associated
with these patients. The 95% CIs around the effect observed in the international trial ranged from 2.1%
lower mortality with fresher RBCs to 5.5% lower mortality with standard-aged RBCs. These data provided
compelling evidence that fresher RBCs conveyed no clinical benefit to the study population included in the
trial, especially as the non-significant direction of effect favoured the standard-aged blood group.
In this report, we analysed the UK cohort according to the predefined analysis plan, and also compared
findings with the international cohort. This analysis was underpowered for the clinical outcomes and was
undertaken in order to assess if any major differences were present in the UK population in terms of
baseline characteristics, transfusion practice, study conduct or clinical outcomes. Our data show that the
critically ill patients included in the UK ABLE trial were very similar to those included in the international
trial. The only possible exception was a greater representation of surgical patients and those undergoing
elective procedures, but these differences were small and unlikely to be clinically relevant. The clinical
outcomes were very similar for both the primary and all secondary outcomes. In addition, the process
measures, especially the transfusion practice based on the mean pre-transfusion haemoglobin concentration,
were very similar.
In summary, the ABLE trial found no clinically or statistically important benefit from transfusing exclusively
RBCs stored for ≤ 7 days compared with the current standard practices used in blood banks. There were
no important differences between the UK cohort and the international cohort in patient characteristics
or outcomes.
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Strengths and weaknesses of the clinical trial
The strengths of the international ABLE trial included the sufficiently large sample size to detect a clinically
important difference in mortality, and a range of relevant secondary outcome measures. The CIs around
the estimations of effect make an important beneficial effect from using fresh RBCs compared with the
current standard very unlikely in the population studied. This population included a heterogeneous
spectrum of critically ill patients whose baseline characteristics were typical of the sickest patients admitted
to ICUs in the UK and other countries. The international participation increased the external generalisability
of the trial results. The design minimised the chance of bias through allocation concealment, blinding and
low loss to follow-up for the outcomes at 90 days. There was a high rate of protocol compliance, which
achieved excellent separation of RBC storage age. The pre-planned sensitivity analyses also all showed
similar effects to the main analysis.
The trial has potential weaknesses. The recruited population was heterogeneous, which means that some
subgroups in whom different effects may occur could have been under-represented. The enrolment criteria
meant that previously transfused patients and those in whom transfusion could not be delayed were not
included. This probably explains the relatively low representation of massively transfused patients, trauma
patients and patients with primary bleeding diagnoses, such as gastrointestinal bleeding. The embedded
audit undertaken during the UK trial showed that 46% of all ICU admissions received RBCs during their
hospitalisation, mostly before and during ICU care. Twenty-three per cent of patients received RBCs before
ICU admission, and were excluded from the trial for this reason. We also found that only 28% of all
transfused patients were potentially eligible for the trial, and only 22% of these were enrolled. By far the
most common reason for non-inclusion was transfusion at night or outside usual working hours. These
data raise the possibility that the patients not enrolled based on inclusion criteria and/or logistic reasons
were systematically different from the trial cohort. As these patients may have been over-represented by
diagnoses or complications that mandated more rapid or larger RBC transfusions, this might limit the
generalisability to all critically ill patients. The transfusion practice was close to current evidence-based
guidelines, which suggest that transfusion triggers close to 70 g/l for most patients, especially in the
absence of cardiovascular disease. However, there was clearly some variation between clinicians and
centres in the use of RBCs. Although this was inevitable in a pragmatic trial in which this aspect of
care was not controlled, it could potentially create some ‘noise’ in the effects observed. Any variation
in transfusion decision-making was balanced between the groups, so the impact of this potential
confounder was unlikely to be important.
Importantly, the ABLE trial did not test the hypothesis that fresh RBCs were superior to ‘old’ RBCs with a
storage duration close to the current maximum storage times of 35–42 days. It is possible that the
additional effects of storage during this period could alter the effectiveness of the blood product. The
conclusions of the ABLE trial are therefore limited to the comparison of the current typical storage age
with exclusively fresher RBCs.
Economic evaluation
We undertook a pre-planned series of analyses that were specific to the UK ABLE trial, and also of
potentially more generic value to critical care economic evaluations. These comprised a cost–utility analysis
of the value of fresh RBCs compared with standard-aged RBCs, a nested study comparing the EQ-5D-3L and
EQ-5D-5L utility scores in critical care survivors and an exploration of factors associated with health-care
resource use and QALYs following critical illness. All analyses used the data collected from the UK ABLE trial
data set.
Cost–utility analysis
Our economic analysis to evaluate the cost-effectiveness of using fresh blood units versus standard-aged
blood for transfusions in critically ill patients in the UK showed that there were no differences in terms of
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costs and outcomes. The univariate sensitivity analysis showed that the results were not sensitive to the
assumptions made, and the probabilistic sensitivity analysis indicated that the probability that use of fresh
blood was cost-effective was close to the probability that standard-aged blood was cost-effective. The
findings mean that there is no reason to prefer fresh blood to standard-aged blood on the basis of
differences in quality or length of life, or on cost grounds.
The main strength of the analysis is that it is based on a large multicentre randomised trial with detailed
information on resource use, utility values and mortality up to 12 months. However, there are several
limitations. First, we assumed that the cost of fresh and standard-aged blood units were the same, but this
might not be true. On the one hand, standard-aged blood might incur extra costs as a result of the longer
storage time; on the other hand, organising blood supplies and blood banks to provide exclusively fresh
blood might incur greater costs, plus there might be a higher likelihood of wasting unused blood. Our
sensitivity analysis showed that when changing the costs of blood, the conclusions do not change. Second,
during the 12-month follow-up we made assumptions regarding the duration of contacts during follow-up,
as this information was not collected in the trial. These costs represent a small proportion of the total costs,
and the mean number of contacts per patient was similar in the two groups, so these assumptions are
unlikely to make any difference to the overall findings. Third, during follow-up the reason for the hospital
appointments and some hospital readmissions were not always stated; we therefore used a diagnosis-specific
unit cost where possible, and an average cost where diagnostic information was not available. Fourth, for
hospital readmissions, if the patient was admitted to the ICU then data were not collected on the number of
days spent in the ICU, only whether or not the patient was admitted to the ICU. We assumed that each ICU
admission lasted 1 day. This would almost certainly underestimate the costs of readmissions, but was unlikely
to affect the relative cost-effectiveness of the two groups, as the number of ICU admissions was small. Fifth,
QALY data were collected using either the EQ-5D-3L or the EQ-5D-5L in different patients; each UK study
centre was randomly allocated to one version. As shown in Chapter 6, the use of different measures did
result in a difference in utility scores by treatment allocation. Sixth, because of the nature of the patients
who are treated in the ICU at randomisation (incapacitated emergency admissions), no baseline data were
collected for the QALYs, so we assumed a baseline value of zero, which is consistent with previous studies.
Further research would be beneficial to investigate the impact and validity of this approach, and if other
methodological approaches should be adopted. Seventh, utility data were collected at two time points only,
6 and 12 months. Data from more frequent measurement of utilities would have been useful, but was not
considered to be feasible given the challenges of complete follow-up in this group. Additionally, more
frequent measurement is unlikely to have affected the results of the economic analysis, given that there were
no between-group differences in any of the primary or secondary outcome measures, and nor were there
differences in utilities at 6 and 12 months. Eighth, we did not have complete data for every participant in the
trial and used multiple imputation. However, conclusions regarding the cost-effectiveness of fresh blood
versus standard-aged blood were the same for analyses using multiple imputation and complete cases.
Ninth, a wider perspective (e.g. societal) could have been taken, including costs to patients, families and
productivity. Given that the trial found no differences in QALYs between the two groups, it is highly unlikely
that this would affect the incremental costs between the two groups and therefore the overall conclusions of
the analysis.
Comparison of the two EuroQol-5 Dimensions versions for assessing health-related
quality of life in critical care survivors
We evaluated two versions of the EQ-5D at different time points and found some evidence of
disagreement between the two measures, even after controlling for differences in patient characteristics.
Although there was some evidence that EQ-5D-5L scores were higher than EQ-5D-3L scores, these
differences did not affect utility scores associated with fresh versus standard-aged blood, which were not
different for either measure at both time points when controlling for differences in patient characteristics.
This result is unsurprising, given the results of the ABLE trial, which found no significant differences in the
primary and secondary outcomes between treatment groups.
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There have been several studies comparing the EQ-5D-5L and EQ-5D-3L in different populations,
generally showing that the EQ-5D-5L performs better than the EQ-5D-3L as a result of reduction in ceiling
effects49–51,53–55,57–59 and ability to discriminate between patient characteristics.52–54,56,57 Some studies have
shown a high level of agreement between the two measures.50,51,54,57,59 There have been no studies
comparing the two instruments in critical care survivors.
There were no differences in ceiling effects between the two utility measures, and there was some
evidence that the EQ-5D-5L discriminated between subgroups of patients with major comorbidities,
while the EQ-5D-3L did not. The lack of a difference in ceiling effects may be a result of the relatively low
proportion of patients in our sample reporting best possible quality of life compared with respondents in
other studies. For example, in our sample, 9–15% of patients reported being in the best possible health
state, compared with 47–56% in a recent study using an English general population sample.49 This
difference is likely to reflect the substantial long-term health burden on patients associated with critical
care survivorship.15
There are two major limitations to this analysis. The first is that the two EQ-5D measures were not collected in
the same patients, so between-measure differences in utility may reflect differences in patient characteristics.
We controlled for a range of patient characteristics, including pre-existing significant comorbid illnesses, but
we cannot rule out the possibility that differences in unobserved patient characteristics may explain the
observed difference in utility scores at 12 months. The second major limitation is the sample size; our study
originally included 359 patients, but mortality, questionnaire non-response and analyses by subgroups meant
that sample sizes in the study were ultimately small, potentially reducing the likelihood of finding statistically
significant differences between groups. A further limitation is that the patient characteristics, especially the
comorbidities, were measured at hospital admission, 6–12 months prior to EQ-5D measurement. This might
partly explain the non-significant impact of many of the patient characteristics on utility scores in our analysis.
On the other hand, the comorbidities were collected in the trial because they are likely to have a significant
impact on health and persist over time. Nonetheless, analyses with repeated characteristic measurement at
the same time as utility measurement would be useful, and would also permit an evaluation of the two
utility measures as health changes over time. Finally, we did not achieve a full response rate to the EQ-5D
questionnaires among survivors; response rates were 53–54% at the two time points and the non-responders
may not be a random sample of trial participants; on the plus side, the response rate was higher than in
another recent study examining differences in utility scores between critical care patients (36%).68
Further research would be beneficial to repeat the analysis with a larger cohort of critical care survivors, using
a study design in which patients completed both EQ-5D questionnaires, along with repeated assessment of
health and other characteristics. This would increase confidence that any observed differences between the
two utility measures did not result from differences in patient characteristics, and would permit more
sophisticated analyses.
Factors associated with health-care costs and quality-adjusted life-years
We evaluated the factors associated with hospital costs and total costs and QALYs up to 12 months after
ICU admission in critically ill adults in the UK. None of the variables in our data was a significant predictor
of utility scores at 6 or 12 months or of QALYs up to 12 months. The lack of an effect may reflect the
limitations of our data set in terms of available measures, sample size and data missingness. Consistent
with previous studies,62 we found that ICU costs were an increasing function of illness severity, measured
in terms of MODS score and mortality. Contrary to previous studies, costs from hospital discharge up to
12 months were largely unaffected by acute illness factors, age or comorbidities, although there was some
evidence that chronic institutionalisation, included as an indicator of pre-existing morbidity was associated
with 12-month costs.15,63
There are several limitations to this analysis. First, our study did not include a control group, for example
hospital patients not admitted to the ICU or a before-and-after comparison of ICU patients, which have
been used in previous studies.15,63 Second, there were limited covariates in our data set, in terms of
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pre-existing morbidities and other variables that have been shown to predict long-term outcomes and
resource use in previous studies, such as prior hospitalisations. Third, the sample size was limited; our study
originally included 357 patients, but mortality and questionnaire non-response meant that sample sizes in
the study were ultimately small, potentially reducing the likelihood of finding statistically significant
differences between groups. We did not achieve a full response rate to the follow-up questionnaires
among survivors; response rates were 45–55% and the non-responders may not be a random sample of
trial participants.
In conclusion, we found that ICU costs were an increasing function of illness severity, measured in terms of
MODS score and mortality. Further research would be beneficial to investigate the factors associated with
longer-term costs and outcomes.
Results in context of other research
Several systematic reviews have been published during the conduct of the ABLE trial. A meta-analysis by
Wang et al.69 in 2012 of 18 observational studies and three RCTs, predominantly in cardiac surgery and
trauma patients, concluded that older blood was associated with an increased risk of death. A larger
meta-analysis by Lelubre and Vincent in 201370 included 55 studies, of which only eight were RCTs. This
showed no superiority of fresher RBCs over a range of morbidity outcomes (infection, bleeding, duration of
MV, multiorgan dysfunction, length of stay) and mortality. Authors commented on significant confounding
factors in interpreting these analyses, namely retrospective designs, heterogeneous populations, small
studies and the exposed volume of RBCs. Sicker patients with comorbidities tend to receive more RBC
units, such that inferring causality of adverse effects to RBC storage duration is challenging, as evidenced
by a meta-analysis, which showed positive results for studies that did not adjust for this compared with
those that did.
A Cochrane review of RCTs assessed the effects of age of stored RBCs in people requiring transfusion.71
Only RCTs were included, with participants of any age (from neonates to adults) requiring transfusion for
anaemia of any aetiology. The primary outcome was mortality within 7 days and 30 days after transfusion,
with longer-term mortality as a secondary outcome. In total, 16 RCTs were eligible for inclusion in the
review with a total of 1864 participants of all ages; five RCTs on neonates, one on paediatric patients
and 10 on adults. All included studies followed similar design and analysis strategies; there were two
randomised groups of participants, one receiving ‘fresher’ blood than the other, implying dichotomous
outcomes, which were examined based on risk ratios when comparing the two groups. There were five
trials dealing with transfusion in low-birthweight neonates, with the rest of the trials dealing with anaemia
(including malarial anaemia in a paediatric population), cardiac surgery and treatment for critical illness,
trauma and the ICU. There were only 2 out of the 16 studies that assigned > 100 patients, with the two
larger trials assigning 377 and 910 patients. Five feasibility trials were also included as precursors to larger
trials, including the two trials that underpinned the ABLE trial.9,10 There were differences recorded between
the included studies in the additive solutions used to preserve RBCs and whether or not RBCs were leuco-
reduced and/or irradiated, and four studies did not report on this information. There were differences
between the protocol definitions and the actual age of stored blood used, and many studies reported
significant protocol violations, often apparently because of daily fluctuations of stored blood availability.
The lack of agreed definitions of the ‘age of blood’ and, as a consequence, the variability of the recorded
cut-off points between the included studies were major impediments in exploring the relationship between
the length of time of stored blood and the risk of transfusion in this and other reviews. The multiple
transfusions required by many patients and the inconsistent reporting of data details regarding the actual
age of transfused blood served as compounding factors for the methodological challenges encountered.
The studies in the review reported in total three groupings for comparison of the RBC product: ‘fresher’,
‘standard practice’ and ‘actively older’ blood. Eight trials compared transfusion of ‘fresher’ with ‘actively
older’ blood, with the remaining eight comparing ‘fresher’ with ‘standard practice’ blood. The definitions
of ‘fresh’, ‘standard’ and ‘older’ were not consistent among studies. In many trials, the ranges overlapped
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such that the distinction between trial groups was small and of questionable relevance. No conclusions
could be drawn from the available evidence from RCTs that preceded the ABLE trial.
In summary, these reviews highlight the lack of high-quality evidence prior to the completion and
publication of the ABLE trial, and the uncertainty regarding the clinical importance of RBC storage age
for clinical outcomes.
An important concurrent RCT to the ABLE trial was RECESS,72 which was a multicentre RCT conducted
between 2010 and 2014. Participants were aged ≥ 12 years and undergoing complex cardiac surgery,
and likely to require RBC transfusion. Patients were randomly assigned to receive leucocyte-reduced RBCs
stored for ≤ 10 days (shorter-term storage group) or for ≥ 21 days (longer-term storage group) for all
intraoperative and postoperative transfusions. The primary outcome was the change in MODS score (range
of 0–24 points, with higher scores indicating more severe organ dysfunction) from the pre-operative score to
the highest composite score through day 7 or the time of death or discharge. The median storage time of
RBCs provided to the 1098 participants who received RBC transfusion was 7 days in the shorter-term
storage group and 28 days in the longer-term storage group. The mean change in MODS score was an
increase of 8.5 points and 8.7 points, respectively (95% CI for the difference: −0.6 to 0.3 points; p = 0.44).
The 7-day mortality was 2.8% in the shorter-term storage group and 2.0% in the longer-term storage group
(p = 0.43); 28-day mortality was 4.4% and 5.3%, respectively (p = 0.57). AEs did not differ significantly
between groups, except that hyperbilirubinaemia was more common in the longer-term storage group.
This trial found no evidence of a clinically or statistically important difference in development of organ
dysfunction or any of the other secondary outcome measures, associated with the storage age of RBCs.
Importantly, RECESS provides similar findings to the ABLE trial in groups at a much lower risk of death,
and compared a fresher RBC storage age group with a group allocated to receive RBCs that were, on
average, 7 days older than the standard age of RBCs used in the ABLE trial control group.
Another relevant trial, INFORM (INforming Fresh versus Old Red cell Management; ISRCTN08118744),73
was published since the main publication describing the ABLE trial. This was a hospital-wide study
randomising any patient requiring a RBC transfusion to receive the freshest versus the oldest available
RBCs in the blood bank during their hospital stay in a 1 : 2 ratio.18 The trial was undertaken in six hospitals
and included 20,858 patients with type A or O blood. Of these patients, 6936 were assigned to the
short-term storage group and 13,922 to the long-term storage group. The primary outcome was in-hospital
mortality, which was estimated by means of a logistic regression model after adjustment for study centre
and patient blood type. The mean storage duration was 13.0 days in the short-term storage group and
23.6 days in the long-term storage group (achieving the pre-planned mean separation of 10 days). There
were 634 deaths (9.1%) in the short-term storage group and 1213 (8.7%) in the long-term storage group
(odds ratio 1.05, 95% CI 0.95 to 1.16; p = 0.34). The results were consistent in three prespecified high-risk
subgroups (patients undergoing cardiovascular surgery, those admitted to intensive care and those with
cancer) indicating consistent lack of differences in three contrasting groups at different risk of short- and
long-term mortality. Importantly, the effects seen in critically ill patients were similar to those found in the
ABLE trial, in whom a similar ‘usual-care’ comparator storage age was compared with an overall ‘fresher’
storage age. The risk of death was lower in the INFORM trial ICU population (older storage age, 12.8%;
shorter storage age, 13.3%), but these results provide evidence that the ABLE trial findings are likely to be
applicable to a large number of ICU patients, despite the narrower inclusion criteria used in the trial.
The TRANSFUSE trial74 (a multi-centre randomised double-blinded Phase III trial of the effect of standard
issue red blood cell blood units on mortality compared to freshest available red blood cell units;
ClinicalTrials.gov NCT01638416) is a large trial in critically ill patients (n = 5000), in which patients
requiring RBC transfusion are randomised to receive either the freshest RBC units available in the blood
bank at the time of request or standard-issue RBCs (similar in design to the INFORM trial).73 This trial is
ongoing and the results are not yet available at the time of writing.
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Implications for practice
The ABLE trial provides evidence that there is no clinical or economic rationale for transfusing exclusively
fresher RBCs to patients at high risk of death in the ICU, when RBC transfusion decisions are at the
discretion of the clinician. Blood banks should not change their current practice of providing standard-aged
RBCs to this patient group, assuming the blood product is typically aged, on average, 20–22 days, and is
leuco-reduced. Taken together with RECESS72 and INFORM73 trial findings, the current evidence base does
not support the routine or widespread use of fresher RBCs more than those provided as usual practice
(with a mean storage age of 20–22 days).
The ABLE trial does not provide evidence that RBCs with an older storage age are as safe as standard-aged
RBCs, especially those with a storage age close to the end of current storage times of 35–42 days. However,
most blood banks and blood services actively manage blood stocks such that the proportion of RBCs
transfused at the end of storage lifespan is relatively small.
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Appendix 2 Participant information sheet
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Appendix 4 EuroQol-5 Dimensions, three-level
version questionnaire
This sample questionnaire has been reproduced with permission from the EuroQol Group.29
Sa
mp
leHealth Questionnaire
English version for the UK
(Validated for Ireland)
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Sa
mp
le
By placing a tick in one box in each group below, please indicate which statements best 
describe your own health state today.
Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
Self-Care
I have no problems with self-care
I have some problems washing or dressing myself
I am unable to wash or dress myself
Usual Activities (e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
Pain / Discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
Anxiety / Depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
APPENDIX 4
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Sa
mp
le
9 0
8 0
7 0
6 0
5 0
4 0
3 0
2 0
1 0
100
0
To help people say how good or bad a health state is, 
we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked 100 and 
the worst state you can imagine is marked 0.
We would like you to indicate on this scale how good or 
bad your own health is today, in your opinion. Please do 
this by drawing a line from the box below to whichever 
point on the scale indicates how good or bad your health 
state is today.
Best imaginable 
health state
Worst imaginable 
health state
Your own health 
state today
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Appendix 5 EuroQol-5 Dimensions, five-level
version questionnaire
This sample questionnaire has been reproduced with permission from the EuroQol Group.29
Sa
mp
leHealth Questionnaire
English version for the UK
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Sa
mp
le
Under each heading, please tick the ONE box that best describes your health TODAY.
MOBILITY
I have no problems in walking about
I have slight problems in walking about
I have moderate problems in walking about
I have severe problems in walking about
I am unable to walk about
SELF-CARE
I have no problems washing or dressing myself
I have slight problems washing or dressing myself
I have moderate problems washing or dressing myself
I have severe problems washing or dressing myself
I am unable to wash or dress myself
USUAL ACTIVITIES (e.g. work, study, housework, family or 
leisure activities)
I have no problems doing my usual activities
I have slight problems doing my usual activities
I have moderate problems doing my usual activities
I have severe problems doing my usual activities
I am unable to do my usual activities
PAIN / DISCOMFORT
I have no pain or discomfort
I have slight pain or discomfort
I have moderate pain or discomfort
I have severe pain or discomfort
I have extreme pain or discomfort
ANXIETY / DEPRESSION
I am not anxious or depressed
I am slightly anxious or depressed
I am moderately anxious or depressed
I am severely anxious or depressed
I am extremely anxious or depressed
APPENDIX 5
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Sa
mp
le
The worst health 
you can imagine
• We would like to know how good or bad your health is TODAY.
• This scale is numbered from 0 to 100.
• 100 means the best health you can imagine.
0 means the worst health you can imagine.
• Mark an X on the scale to indicate how your health is TODAY.
• Now, please write the number you marked on the scale in the box 
below.
 
The best health 
you can imagine
YOUR HEALTH TODAY =
10
0
20
30
40
50
60
80
70
90
100
5
15
25
35
45
55
75
65
85
95
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Appendix 6 Health economic questionnaires used
in the Age of BLood Evaluation trial
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